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ABSTRACT 
Lei Li 
FUNCTIONS OF RAT ACYL-COA SYNTHETASES IN BACTERIA AND 
MAMMALIAN CELLS  
(Under the direction of Rosalind A. Coleman) 
 
    Long chain acyl-CoA synthetase (ACSL) activates long chain fatty acids in the initial 
step of lipid metabolism, and provides substrates for both anabolic and catabolic pathways.  
Dysregulation of fatty acid partitioning between these opposing pathways results in cellular 
lipid accumulation, which may cause obesity and lipotoxicity.  We hypothesized that ACSL 
isoforms play a critical role in fatty acid channeling into different metabolic pathways and 
that regulation of ACSL may change the fatty acid channeling.  This dissertation describes 
three independent projects that examined the function of rat ACSL isoforms in lipid 
metabolism and their acute regulation by phosphorylation. 
 
    Using an E. coli model with its endogenous ACSL mutated (fadD), we demonstrated 
that although all rat ACSL isoforms partially rescued fatty acid transport, β-oxidation, and 
phospholipid synthesis, only ACSL5 supported growth on oleate as the sole energy and 
carbon source.  This study supported the hypothesis that ACSL isoforms are functionally 
different and prompted the subsequent study on function of ACSL1 in lipid metabolism.  
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Using an adenovirus that carries an ACSL1 cDNA, we overexpressed rat ACSL1 in primary 
hepatocytes and examined the effects on metabolic pathways.  Consistent with our 
hypothesis that individual ACSLs partition fatty acid, we found that ACSL1 overexpression 
increased oleate incorporation into diacylglycerol and phospholipids, but not triacylglycerol, 
and decreased cholesterol ester synthesis.  Together with the finding from a previous study 
in our lab with ACSL5 overexpression, these data provided direct evidence of different fatty 
acid channeling by ACSLs.  We then studied the potential acute phosphorylation regulation 
of ACSL1 and ACSL5 in 3T3-L1 adipocytes and hepatocytes.  We identified 
phosphorylated threonine 192 on ACSL5, and detected ACSL5 and ACSL1 with 
phosphorylated serine residues.  These data were the first to show that ACSL could be 
phosphorylated, and that phosphorylation could occur on distinct residues among different 
ACSL isoforms.  The importance of this dissertation also lies in directing future research on 
mechanisms of specific role of individual ACSL isoforms and potential clinical implication 
for obesity and its related metabolic diseases. 
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CHAPTER I
INTRODUCTION 
1.1 Lipid homeostasis and fatty acid partitioning 
    In cells, a system of metabolic and signaling pathways maintains lipid homeostasis and 
normal cell function.  Free fatty acids, delivered from exogenous transport, de novo 
synthesis, or released from hydrolysis of triacylglycerol (TAG) and phospholipids (PL), can 
enter multiple pathways, primarily oxidative or biosynthetic pathways.  Dysregulation of 
fatty acid partitioning between these two opposing pathways results in cellular TAG 
accumulation.  In adipose tissue, TAG accumulation causes an increase of both adipocyte 
size and numbers, which develops to obesity.  In non-adipose tissues with limited capacity 
for lipid storage, TAG accumulation causes cellular dysfunction or cell death, often referred 
as lipotoxicity and lipoapoptosis (1,2).  Lipotoxicity in skeletal muscle, liver, pancreas and 
heart, is believed to be associated with insulin resistance, non-alcoholic steatohepatitis (NASH), 
impaired glucose-stimulated insulin secretion, and cardiomyopathy (1,2).  Obesity and its 
related diseases such as diabetes, hypertension and cardiovascular diseases, often called 
metabolic syndrome, produce an alarming health challenge (3).  Studying how fatty acids 
are directed into different pathways will provide an understanding of the etiology of obesity 
and related diseases, and hence provide potential targets for treatment.  
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    This dissertation research is focused on the role of long-chain acyl-CoA synthetases 
(ACSL) in channeling fatty acid among specific pathways of lipid metabolism.  
 
1.2  Fatty acid activation by acyl-CoA synthetase to acyl-CoA 
    Scheme 1.1 provides an overview of ACSL providing long chain acyl-CoAs for 
multiple downstream pathways.  This section will review the role of ACSL in fatty acid 
transport and activation, as well as additional functions of acyl-CoAs in cells. 
 
1.2.1 Activation of fatty acids for downstream lipid metabolism 
    In the initial step of lipid metabolism, long chain fatty acids are converted to acyl-CoA 
thioesters by long chain acyl-CoA synthetases (ACSL) before entering downstream pathways 
(4).  ACSL activates fatty acids in a two-step reaction 1) the formation of a fatty acyl-AMP 
intermediate molecule with pyrophosphate release and 2) the formation of fatty acyl-CoA 
with the release of AMP (5). The hydrolysis of pyrophosphate renders this reaction 
irreversible.   
1) fatty acid + ATP → fatty acyl-AMP + pyrophosphate 
2) fatty acyl-AMP + CoA → fatty acyl-CoA + AMP 
 
    The products of this reaction, long-chain acyl-CoAs (LC-CoAs), with high energy 
thioester bonds, are substrates for both catabolic pathways to provide energy via β-oxidation, 
and anabolic pathways to synthesize complex lipids such as triacylglycerol (TAG), 
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diacyglycerol (DAG), PL and cholesterol ester (CE) (Scheme 1.1).  During β-oxidation, 
LC-CoAs are converted to acyl-carnitines by mitochondrial carnitine palmitoyltransferase 1 
(CPT1) and translocated into mitochondria for further degradation.  During the de novo 
synthesis of glycerolipids, acyl-CoAs are transferred to glycerol-3-phosphate by 
mitochondrial and microsomal sn-glycerol-3-phosphate acyltransferases (GPAT) to 
synthesize lysophosphatidic acid (LPA).  Balance between these two opposing lipid 
metabolic pathways is determined by nutritional and physiological conditions.  ACSL 
functions at this branch point by providing substrates for diverse pathways.  Identification 
of ACSL in all organisms for which genomic sequence information is available testify to the 
essential nature of this enzyme (6).   
 
1.2.2 Long chain acyl-CoA synthetase in fatty acid transport 
    In addition to activating fatty acids for metabolic pathways, ACSL might participate in 
fatty acids import by metabolically trapping them as CoA thioesters after transport into the 
cell (7,8).  This so called “vectorial acylation” process, is proposed to describe the role of 
FadD, the ACSL in Escherichia coli (E. coli), in activating exogenous long-chain fatty acids 
(LCFAs) concomitant with transport across the inner membrane (9).  It has been proposed 
that FadD moves to the inner membrane, where it retrieves and activates LCFAs into 
membrane impermeable acyl-CoAs, thus rendering LCFA transport unidirectional (10,11).  
In fact, import of [3H]oleate is abolished in a ∆fadD strain, and specific mutations in FadD 
not only reduce or abolish enzyme activity but likewise reduce or abolish the import of 
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Scheme 1.1.  Long chain fatty acids, from exogenous or endogenous sources, are 
converted to long chain acyl-CoAs before entering multiple downstream pathways.  
Acyl-CoAs are substrates for lipid metabolism in the two opposing pathways, anabolic for 
complex lipid synthesis such as TAG, PL and cholesterol ester, and catabolic for β-oxidation 
to provide energy.  Balance between these two primary lipid metabolic fates is determined 
by enzyme activity, nutritional status, and physiological conditions.  Disturbance of this 
balance is linked to lipid accumulation and lipotoxicity, common to obesity and insulin 
resistance.  ACSL also provides acyl-CoAs for other cellular processes, such as allosteric 
regulation of enzyme activity, protein acylation, membrane fusion and signal transduction.  
Acyl-CoAs can be synthesized in nuclei or transported to nuclei, where they might serve as 
ligands for transcription factors such as PPARα and HNF-4α and elicit a broad range of 
effects.  ACSL, long-chain acyl-CoA synthetase; DAG, diacylglycerol; LPA, 
lysophosphatidic acid; PA, phosphatidic acid; PL, phospholipids; TAG, triacylglycerol.
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exogenous LCFAs, suggesting a specific coupling between LCFA activation and import (12).  
Biochemical studies with isolated plasma membrane vesicles from E. coli directly 
demonstrate that long chain fatty acid uptake occur only when vesicles contain the enzyme 
and its substrates CoASH and ATP (13).  The importance of ACSL in fatty acid uptake is 
also shown in yeast.  Fatty acid uptake is impaired in a Saccharomyces cerevisiae strain 
with mutations in Faa1 and Faa4, two yeast ACSLs (14).  The growth of this mutated strain 
is completely eliminated when endogenous fatty acid synthase is inhibited with cerulenin. 
These studies suggest that esterification of fatty acid is coupled with transport.  
 
    Much evidence suggests that ACSL also plays a role in fatty acid transport in 
mammalian cells.  ACSL1 is one of the two adipocyte proteins that facilitate the import of 
fatty acid in a functional screen study using an expression cloning approach (15).  When 
overexpressed in NIH fibroblasts, ACSL1 increases fatty acid uptake 8-fold, and has 
synergistic effects with fatty acid transport protein 1 (FATP1) (16).  In fact, FATP1 exhibits 
acyl-CoA synthetase activity with a broad substrate specificity.  It is proposed to enhance 
fatty acid uptake by generating membrane impermeable acyl-CoAs (17-19).  Moreover, 
overexpressed ACSL1 and FATP1 coimmunoprecipitate in 3T3-L1 adipocytes, indicating 
that a physical interaction between ACSL1 and FATP1 might exist (20).  In 3T3-L1 
adipocytes, fatty acid uptake is inhibited 84% by 10 µM triacsin C, an inhibitor of acyl-CoA 
synthetase activity (21), indicating that fatty acid uptake is dependent on vectorial acylation 
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in 3T3-L1 adipocytes.  When another isoform, ACSL5, is overexpressed in McArdle 
RH-7777 rat hepatoma cells, exogenous fatty acid uptake is also increased 30% (22), despite 
the intracellular location of ACSL5 on mitochondria and endoplasmic reticulum (ER), 
suggesting that metabolism driven by ACSL may also contribute to fatty acid uptake. 
 
1.2.3 Additional functions of long chain acyl-CoAs 
    In addition to being substrates for lipid metabolic pathways, LC-CoAs also play an 
important role in a broad range of intracellular processes (23-25) (Scheme 1.1).  LC-CoAs 
regulate enzymes allosterically.  For example, LC-CoAs inhibit hexokinase (26) and 
pyruvate dehydrogenase (23) in glucose metabolism, and inhibit acetyl-CoA carboxylase and 
ACSL in lipid metabolism (23).  In pancreatic β-cells, LC-CoA esters activate 
ATP-sensitive K+ (KATP) channels (25,27), modulate intracellular Ca2+, activate atypical PKC 
isoforms (23,28), and directly stimulate exocytosis resulting in insulin secretion (29-31).  
 
    The covalent attachment of fatty acids to proteins (acylation) is a widespread 
post-translational modification, which mediates protein targeting, vesicle budding or fusing 
and signal transducing (32).  One of the most common acylations, palmitoylation occurs on 
many important signaling proteins such as the G protein coupled receptor, some Gα subunits 
and Ras protein (33).  Palmitoylation also provides mechanisms to regulate rafts and/or 
caveolae targeting and protein-protein interaction, thus affecting a wide variety of signaling 
pathways (33).  In integral membrane proteins such as the G protein coupled receptors, 
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palmitoylation occurs on cysteines that are either close to the transmembrane 
domain/cytoplasmic domain boundary or located in the cytoplamic domain (33).  In 
peripheral membrane proteins such as Src family and Gα subunits, palmitoylation occurs at a 
cysteine near myristoylation sites and this dual acylation is required for stable membrane 
association (33,34).  Peripheral membrane proteins can also be palmitoylated at a cysteine 
several amino acids upstream from the prenylation site, a cysteine in the C-terminal amino 
acid motif, the CAAX box (C = cysteine, A = aliphatic residue, and X = any amino acid) (33).  
Although protein palmitoylation by palmitoyl acyltransferases (PAT) has been found in 
fractions including plasma membrane, Golgi and mitochondria, the sources of the 
palmitoyl-CoA is unknown.  Further studies need to be done on whether acyl-CoA binding 
proteins (ACBP) send acyl-CoAs to subcellular PATs, or specific ACSL isoforms associate 
with PAT in different organelles.   
 
    Additionally, studies from bacteria, yeast, and mammalian cells also imply that 
acyl-CoAs might be natural ligands for transcription factors and hence play a broader role in 
affecting gene expression (23,24,35).  In E. coli, binding of LC-CoAs to the transcription 
factor FadR causes significant conformational changes in both the acyl-CoA binding domain 
and the DNA binding domain.  The acyl-CoA binding renders FadR unable to bind cognate 
operators and allows transcription of target genes (36,37).  In mammalian cells, both 
unsaturated and saturated LC-CoAs bind PPARα with high affinity and elicit conformational 
changes in PPARα, which increases co-activator recruitment (38,39).  Acyl-CoAs may also 
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act as ligands for hepatic nuclear factor 4α (HNF-4α) and regulate its transcriptional activity 
as a function of their chain length and degree of unsaturation (40).  In fact, significant 
amounts of LC-CoA are present in rat liver nuclei (~ 0.32 nmol/g wet rat liver) (41).  The 
high performance liquid chromatography profile of nuclear acyl-CoAs is distinct in that the 
nuclear acyl-CoA pool contains predominantly C18:3 and C16:1 acyl-CoAs, whereas the 
total liver acyl-CoA pool contains predominantly C20:4, C18:2, C18:1, and C16:0 acyl-CoAs 
(41).  Since ACS activity is present in rat liver nuclei (42) and adipocyte nuclei (43), and 
ACSL1 protein is found in adipocyte nuclei fractions (16), specific ACSL isoform(s) might 
contribute to the formation of distinct nuclear acyl-CoA pool for gene expression regulation. 
 
1.3 Long chain acyl-CoA synthetase isoforms 
    Scheme 1.2 shows the conserved domains of ACSL family in E. coli, yeast, rodent and 
human.  This section covers the information on the structure, enzyme kinetics, expression 
pattern, location, and regulation of ACSL isoforms. 
 
1.3.1 Structure 
    Acyl-CoA synthetases (ACS) have been classified by their preferences for short, 
medium, long, and very long chain fatty acids (44).  Long-chain ACS (ACSL) activates 
fatty acids of 12 to 22 carbons.  Since the cloning of rat ACSL1 in 1990 (45), four 
additional ACSL proteins, ACSL3 (46), ACSL4 (47), ACSL5 (48) and ACSL6 (49), were 
identified, each the product of a separate gene.  The five rat ACSLs form two subfamilies.    
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Scheme 1.2.  Conserved domains of the long chain acyl-CoA synthetase (ACSL) family.  
Sequence alignment (ClustalW alignment http://www.ebi.ac.uk/clustalw/) shows two highly 
conserved regions in ACSL isoforms from bacteria to human, a putative ATP-AMP signature 
motif and a FACS (fatty acyl-CoA synthetase) signature motif.  The ATP/AMP signature 
motif contains two highly conserved sequence elements, and is common to all members of 
the adenylate-forming family.  The more highly conserved FACS signature motif, only 
shared by ACSL isofoms, contains several hydrophobic residues (leucine, isoleucine or 
valine), which might comprise part of fatty acid binding pocket (7).     
 
 
 
ACS1, 5 and 6 (originally ACS2, (50)) share ~60% amino acid identity with each other, but 
less than 30% with ACSL3 and ACSL4.  The latter two share 63% amino acid identity (51).  
These five ACSL isoforms have been identified and characterized in mouse and humans 
(44,50,52).  In addition to the diversity of isoforms from individual genes, splice variants of 
mRNAs and proteins of ACSL occur in human and rodents (50).  Some splice variants such 
as human ACSL3 encode transcripts with varying untranslated regions, but are translated as 
the same proteins (50).  Some splice variants encode a longer transcript such as human 
286Faa1p (yeast)
Faa4p (yeast)
N
N
TMI YTSGS GEPKGVVLKHS
TMI YTSGS GTPKGVVLTHY
IL GYGLTET
IL GYGLTEG
DGWF
DGWFRTGDIAEWTPKGQVKIIDRKK
KTGDIGEWEANGHLKIIDRKK
FadD (E. coli) NQL YTGGTTGVAKGAMLTHR EL GYGLTEC NGWLHTGDIAVMDEEGFLRIVDRKK431211 230 354 362 455
531267 453 461 555
527267 286 449 457 551
ACSL1 (human) TCI FTSGT GNPKGAMVTHRN EY GYGQTEC DGWLHTGDIGKWLPNGTLKIIDRKK533273 292 455 463 557
ACSL1 (mouse) TCI FTSGT GNPKGAM I THQN EY GYGQTEC DGWLHTGDIGKWLPNGTLKIIDRKK534274 293 456 464 558
ACSL1 (rat) TCI FTSGT GNPKGAMVTHQN EY GYGQTEC DGWLHTGDIGKWLPNGTLKIIDRKK534274 293 456 464 558
TMI YTSGS GI PKGVM I SHSNACSL3 (rat) GQGYGLTES QRWLC FDPDGCLKIIDRKKTGDIGE557284 303 472 480 581
TMV YTSGS GRPKGVMMHHSACSL4 (rat) N GQGYGLTES QRWFC FHPDGCLQIIDRKKTGDIGE422234 253 430 507 531
TCI FTSGT GDPKGAMLTHQNACSL5 (rat) EF AYGQTEC DGWLHTGDIGRWLPNGTLKIIDRKK258 277 448 518 542440
TCV FTSGT GNPKGAMLTHGNACSL6 (rat) DGWLHTGDIGKWLPEGTLKIIDRKKEY GYGQTEC273 292 463 533 557455
ATP/AMP motif FACS motif
200-275 aa 150-170 aa 70-75 aa 110-130 aa
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ACSL4, which encodes a protein with 41 more amino acids at the N terminus (53,54).  We 
also identified splice variants of rat ACSL6 that have 12 different amino acids, as a result of 
alternative exon use (51).    
 
    Multiple sequence alignments of ACSL identified two highly conserved regions in 
ACSL isoforms from bacteria to human, a putative ATP-AMP signature motif and a fatty 
acyl-CoA signature motif (FACS signature motif) (Scheme 1.2).  The ATP-AMP signature 
motif contains two highly conserved sequence elements, common to all adenylate-forming 
enzymes, including firefly luciferase (7,55).  This ATP-AMP motif might contribute to the 
binding of ATP and/or to the formation of the adenylated enzyme intermediate because ATP 
is the one substrate common to all members (12).  The FACS signature motif, only shared 
by ACSL isoforms, contains several hydrophobic residues and is predicted to form the fatty 
acid binding pocket (7).  Site-directed mutation in these motifs in FadD, the ACSL of E. coli, 
further supports the idea that these sites are important for catalytic activity (12,55).  For 
example, fadDE361A in the ATP-AMP signature results in an enzyme with no measurable 
activity in E. coli (12).  Seven of 18 site-directed mutations in the FACS signature motif 
lower the affinity for fatty acids and alter fatty acid chain length specificity (55).  Using 
affinity-labeled LCFA [3H]9-p-azidophenoxynonanoic acid, a peptide sequence 
422PDATDEIIK430 is defined as the fatty acid binding site in FadD.  This site overlaps the 
FACS signature motif, suggesting that this is part of the fatty acid binding domain (56).    
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    Due to the difficulty in purifying membrane proteins, no NMR or X-ray crystal structure 
data are available for mammalian ACSLs.  However, a distantly related ACSL from the 
thermophilic bacterium Thermus thermophilus HB8, ttLC-FACS, has been crystallized, 
which provides insight into the catalytic mechanism for bacterial ACS (57).  The crystal 
structure from ttLC-FACS suggests that ttLC-FACS forms a homodimer with interactions at 
the N terminus via intermolecular salt bridges and a hydrogen bond.  It is proposed that 
mammalian ACSLs might also form homodimers because those residues that form the bonds 
are highly conserved (57).  The crystal structure of ttLC-FACS also suggests that a fatty 
acid-binding tunnel exists at the N terminus.  In order to study the importance of this tunnel 
for substrate specificity, we generated rat ACSL4 mutations at residues that correspond to 
those in the fatty acid-binding tunnel based on ttLC-FACS sequence alignments.  The 
mutation of 410Glycine (G410L) and 291serine (S291Y), which are located at the entry and 
termination of the potential fatty acid-binding tunnel, respectively, resulted in an inactive 
ACSL4 or ACSL4 with diminished affinity for C20:5 and C22:6 (58).  These data suggested 
that specific residues around the proposed tunnel contributed to substrate specificity and 
catalytic activity.   
 
1.3.2 Substrate preferences and enzyme kinetics 
    Although ACSL isoforms catalyze the activation of fatty acids by the same reaction, 
they differ in their substrate preferences and enzyme kinetics.  Despite a wide range of fatty 
acid substrates, the ratios of C16:0 ACS activity to C12:0 ACS activity are 0.76 and 1.03 for 
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ACSL1 and ACSL6, respectively (49).  ACSL3 uses C12:0 and C14:0 most efficiently 
among saturated fatty acids and C20:4 (arachidonic acid) and C20:5 (eicosapentaenoic acid) 
among unsaturated fatty acids (46).  ACSL4 has a marked preference for C20:4 
(Km = 15 µM) and C20:5 (Km = 12 µM), compared to C16:0 (palmitic acid) (Km = 100 µM) 
(47).  ACSL1 and ACSL5 activate shorter-length fatty acids (16–18 carbons) with nearly 
equal efficiencies, ACSL3 and ACSL4 activate C20:4 (n-6) and C20:5 (n-3) with the greatest 
efficiency, and ACSL6 preferentially promotes C22:6 (docosahexaenoic acid) metabolism in 
neuronal cells (59,60).  Purified recombinant ACSL1, 3, 4, 5 and 6 have similar apparent Km 
values for CoA and palmitic acid, but different Km values for ATP.  The ATP affinity of 
ACSL4 is approximately 19-, 13-, 20-, 44-, and 360-fold higher than that of ACSL1, ACSL3, 
ACSL5, ACSL6_v1 and ACSL6_v2, respectively (21,51).  ACSL1 is also more sensitive to 
heating and inhibition by NEM, which modifies sulfhydryl groups (21,51).  A direct 
competition assay to compare the fatty acid preferences shows differences among ACSL3, 4, 
and 6, the three main ACSL isoforms in brain (Appendix 6.2, Figure 6.3).  ACSL3 prefers 
C18:3 to C16:0 and C22:6, and ACSL4 prefers all the polyunsaturated fatty acids (PUFA) 
tested, especially C20:4 and C20:5.  The 12 amino acids difference between ACSL6_v1 and 
ACSL6_v2 renders preference of C18:2 and C18:3 to C16:0 by variant 1 and preference of 
C22:6 and C18:3 to C16:0 by variant 2.   
 
1.3.3 Tissue and developmental expression pattern and subcellular location 
    ACSL isoforms are expressed to various degrees in different tissues.  When rat ACSL1 
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was first cloned, its mRNA was only found in liver, heart, and adipose tissue, not in lung, 
small intestine, or brain (45).  In a more extensive study using quantitative real-time PCR, 
we found that ACSL1 mRNA was highest in brown adipose tissue, gonadal adipose tissue, 
liver and heart, low in skeletal muscles and very low in brain (61).  ACSL3 mRNA is 
expressed at highest level in brain and high level in testis, but at low levels in all other tissues 
examined (46,61).  The highest expression of ACSL4 is in adrenal gland and other 
steroidogenic organs (47).  ACSL4 is expressed at a relatively high level in liver and brain, 
and at markedly lower levels in other tissues including adipose tissues, skeletal muscle, heart, 
testis, but not in small intestine (47,61).  In addition, in human brain, ACSL4 is specifically 
expressed in neurons but not in glial cells (54).  ACSL5 is expressed most abundantly in 
small intestine, liver, and brown adipose tissue, but relatively low in lung, adrenal gland, and 
white adipose tissue (48,61).  ACSL6 mRNA is most abundant in brain, and to a lesser 
extent, in gastrocnemius and soleus muscles, but is low in heart and brown adipose tissue and 
undetectable in white adipose tissues and liver (49,61).  Distinct tissue distribution and 
enzyme characteristics of each ACSL isoform suggest that ACSL isoforms contribute to 
specific lipid metabolic pathways in different tissues.  For example, abundant expression of 
ACSL1 in adipocytes might provide acyl-CoAs for TAG synthesis and storage, and high 
level of PUFA preferring ACSL3 and ACSL6 in brain might provide acyl-CoAs for PL 
synthesis.  
 
    ACSL isoforms also display unique development expression patterns.  In rat 
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reaggregated brain cells, a model for developing brain, from day 7 to day 49, ACSL3 and 
ACSL6 mRNA increase 3-fold and 7-fold, respectively, whereas ACSL1 mRNA remain low 
and unchanged (62).  In PC12 neuron cells that use fatty acid primarily for PL synthesis, 
before differentiation the mRNA levels of ACSL4 and ACSL5 are 3- and 5-fold of those of 
ACSL1, 3, and 6, respectively (63).  After PC12 cell differentiation, ACSL4, ACSL5 and 
ACSL6 mRNAs are increased by 63%, 110% and 27%, respectively, whereas levels of 
ACSL1 and ACSL3 mRNAs are unchanged (63).  Additionally, during the development of 
rat brain, ACSL3 mRNA is high during early postnatal period (5-15 d) and decreases from 
day 20 to adulthood.  In contrast, ACSL6 mRNA increases gradually from postnatal day 15 
and reaches a maximum level in the adult.  ACS1 mRNA levels display no change during 
brain development (46).  The unique developmental patterns of ACSL isoforms suggest that 
they play different tissue-specific roles during development. 
 
    Additionally, ACSL isoforms have specific subcellular distributions.  Using 
fractionation techniques, it has been shown that in rat liver, ACSL1 is located in ER, 
mitochondrial-associated membrane (MAM) and cytosol, but not in mitochondria (64).  
ACSL4, a peripheral membrane protein, is abundant in MAM and is the only ACSL isoform 
present in peroxisomes in rat liver (65).  In human brain alternative splicing encodes a 
longer transcript, which produces a brain-specific ACSL4 isoform with 41 additional 
amino-terminal, hydrophobic amino acids (54).  Consistent with predicted location in ER, 
immunohistochemical staining shows location of this splicing variant of ACSL4 in the outer 
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nuclear membrane (54).  ACSL5 is the only isoform identified on the mitochondria outer 
membrane in liver (64,66) and is also located on the ER when overexpressed in McArdle rat 
hepatoma cells (22).  In 3T3-L1 adipocytes, ACSL1 is enriched in ER and plasma 
membrane (16).  Distinct subcellular locations of ACSL isoforms might link them to 
specific metabolic features of each organelle.  For example, ACSL1 and ACSL4 in MAM 
may provide acyl-CoA for glycerolipid synthesis, and ACSL4 in peroxisomes may channel 
fatty acids for peroxisomal oxidation.  
 
1.3.4 Physiological regulation 
    In addition to the specific pattern during brain development and cell differentiation as 
mentioned above, expression of ACSL isoforms differs under varying physiological 
conditions.  In rat liver, both ACSL1 and ACSL5 mRNA are increased by a high sucrose 
diet, but a high fat diet increases only ACSL1 mRNA (45,48).  At the protein level, fasting 
for 48 h decreases ACSL4 protein by 47% in rat liver, but increases ACSL5 protein by 82%, 
and refeeding rats after fasting results in a significant increase of both ACSL1 and ACSL4, 
but not ACSL5 (64).  In liver from genetically obese (ob/ob) mice, which have leptin 
deficiency and display severe obesity and insulin resistance, ACS activity is lower in 
mitochondria but higher in ER when compared with control mice (67).  Although ACS 
activity in these organelles is comprised of more than one isoform, more activity in ER 
suggests increased substrate availability for esterification.  Streptozotocin-induced 
insulin-dependent diabetes (4 wk) and fasting for 24 h both repress ACSL6 mRNA in rat 
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heart, with no significant effects on the other ACSL isoforms (68).  Conversely, insulin 
increases the mRNA levels of ACSL1, ACSL3, and ACSL6, with no effect on those of 
ACSL4 or ACSL5 in rat cardiomyocytes (68).  Additionally, adrenocorticotropin (ACTH) 
increases the protein level of ACSL4 in rat adrenal gland and in adrenocortical Y1 cells after 
30 min incubation and 15 min stimulation, respectively (69).  In MA-10 Leydig cells, 
triacsin (ACSL4 inhibitor) blocks 8Br-cAMP stimulated progesterone production, indicating 
that ACSL4 is essential in steroidogenesis (69).   
 
1.3.5 Regulation associated with pathological conditions 
    ACSL isoforms have been found to change under certain pathological conditions related 
to tumorgenesis.  Human ACSL4 mRNA and protein levels are increased in colon 
adenocarcinomas, particularly colon epithelium and crypts, compared with adjacent normal 
tissues from the same patients (70).  Upregulation of ACSL4 is also present in many colon 
carcinoma cell lines (70).  An in vitro study with Int407 cells, an intestinal epithelial cell 
line, shows that the tumor promoter PMA increases ACSL4 mRNA (71).  ACSL5 mRNA is 
also upregulated in human colorectal cancer tissues (72) and in endometrioid 
adenocarcinomas (73).  Moreover, ACSL1 and ACSL4 are increased in terminal ileum and 
colon of inflammatory bowel disease patients, whereas other ACSL isoforms remain 
unchanged (74).  Although the causality between the change of ACSL isoforms and these 
diseases is not established, these observations suggest that ACSL isoforms are linked to 
metabolic changes or demand under these pathological conditions.  For example, the 
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upregulation of C20:4-preferring ACSL4 in colon adenocarcinoma might decrease the 
cellular level of unesterified C20:4 and thereby prevent apoptosis, which promotes 
carcinogenesis (70).  The increase of ACSL1 and ACSL4 in terminal ileum and colon of 
inflammatory bowel disease patients might provide fatty acyl-CoAs for PL synthesis, which 
can serve as precursors for inflammatory mediators, or support membrane integrity and 
epithelial barrier function of the affected intestine (74).   
 
    In humans, a 2-Mb deletion of Xq22.3 containing ACSL4 and four other genes is linked 
to the AMME contiguous gene deletion syndrome, characterized by Alport syndrome, 
midface hypoplasia, mental retardation and elliptocytosis (75,76).  Two point mutations in 
ACSL4 have been identified in patients with nonspecific X-linked mental retardation (54).  
One results in the substitution of the conserved 529Arg with serine in the FACS signature 
motif, the other one causes a premature stop mutation and a shortened protein without the 
FACS signature motif.  Both mutations result in non-functional proteins because 
arachidonoyl-CoA (C20:4) synthetase activity decreases 88% in lymphoblastoid cells from 
these patients (54).  The nervous system has the highest concentration of PUFAs (especially 
C:22:6), which are primarily incorporated into the sn-2 position of PLs and are critical for 
normal neurodevelopment (59).  Since ACSL4 prefers C20:4 and C22:5 and other PUFA, a 
mutation in ACSL4 might impair PL synthesis and brain development.  Alternatively, 
mutation of ACSL4 might increase the availability of C20:4 and C22:6 and promote 
C20:4/C22:6-induced apoptosis and excessive loss of brain cells (59,70).  
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1.4 Fatty acid partitioning by acyl-CoA synthetase 
    The fundamental question arising from the observations that ACSL isoforms have 
different enzyme kinetics, unique locations and regulations is why there is more than one 
ACSL isoform and what the function of each is.  Based on the evidence described above 
and below, we believe that ACSL plays a critical role in fatty acid channeling.  That is, 
different ACSL isoforms provide fatty acyl-CoAs to specific downstream metabolic 
pathways, and regulation of different isoforms may change the fatty acid partitioning 
(4,44,66).  Functionally independent acyl-CoA pools might exist which are channeled 
towards specific fates instead of being freely available for all downstream pathways (Scheme 
1.3).   
 
1.4.1 Sensitivity to ACSL inhibitors – differentiation of ACSL isoforms 
    Although ACSL isoforms have overlapping fatty acid substrates, to some extent，they 
can be differentiated by competitive inhibitors such as triacsin C and thiazolidinediones 
(TZD).  Triacsin C is the most potent inhibitor among triacsins (A, B, C, and D), 
fungal-derived alkenyl-N-hydroxytriazenes, which inhibit ACS activity by competing with 
LCFA for binding to active sites (77,78).  Triacsin C strongly inhibits purified ACSL1, 3, 
and 4, with apparent Ki values of 4 µM, 5.5 µM and 7.5 µM, respectively, but has little effect 
on purified ACSL5 or ACSL6 (21,51).  If the hypothesis of fatty acid channeling by ACSL 
is true, then pathways that are linked to triacsin C sensitive ACSL isoforms would be 
inhibited by triacsin C.  In fact, several studies showed that triacsin C selectively inhibits  
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Scheme 1.3.  Proposed model of fatty acid channeling by long chain acyl-CoA synthetases 
(ACSL).  Exogenous LCFA released from albumin can enter cells either through diffusion 
or through facilitated transport.  Fatty acid transport proteins include FATP family members, 
CD36/FAT, and in some cases, ACSL.  The acyl-CoA synthetase activity of FATP and 
ACSL may contribute to LCFA uptake by trapping LCFA in the form of LC-CoA upon 
transport.  Imported exogenous LCFA and endogenous LCFA derived from de novo 
synthesis or from lipolysis of cell lipids associate with FABP, and are transferred to ACSL 
isoforms.  LCFA is activated by ACSL to LC-CoA, which enters further metabolism, or is 
bound by ACBP.  ACSL isoforms located in different subcellular organelles create 
independent LC-CoA pools and channel LC-CoAs into specific downstream pathways, 
probably via protein-protein interactions with local acyltransferases or with ACBP.  ACSL 
in the endoplasmic reticulum may provide acyl-CoA to erGPAT for TAG and PL synthesis, or 
to ACAT for CE synthesis.  ACSL in mitochondria may provide separate LC-CoA pools to 
mtGPAT for TAG synthesis, or to CPT1 for β-oxidation.  ACSL in peroxisome can provide 
LC-CoA for peroxisomal oxidation.  ACAT, acyl-CoA: cholesterol acyltransferase; ACBP, 
acyl-CoA binding protein; ACSL, long-chain acyl-CoA synthetase; CE, cholesterol ester, 
CPT1, carnitine palmitoyltransferase 1; FABP, fatty acid binding protein; erGPAT, 
endoplamic reticulum sn-glycerol-3-phosphate acyltransferase; mtGPAT, mitochondrial 
sn-glycerol-3-phosphate acyltransferase; LC-CoA, long-chain acyl-CoA; LCFA, long chain 
fatty acid. 
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only some lipid metabolic pathways.  For example, when human fibroblasts are incubated 
with 10 µM triacsin C, oleate (C18:1) incorporation into both TAG and CE decreases 91%, 
while incorporation into PL is not impaired, indicating that triacsin C sensitive ACSL  
isoforms provide acyl-CoAs for TAG and CE synthesis but not for PL synthesis (79).  
Differential inhibition is also observed in hepatocytes isolated from starved or fed rats.  
Triacsin C (10 µM) inhibits oleate (1 mM) incorporation into TAG 70% in hepatocytes from 
fed rats, but it has little effect on oleate incorporation into CE, PL, or β-oxidation (80).  In 
hepatocytes from 24-h-starved rat, triacsin C inhibits oleate (1 mM) incorporation into TAG 
and CE 40% and 44%, respectively, and into PL around 15% (80).  Since ACSL1, 3, 4, 5, 
and an unidentified triacsin C sensitive mitochondrial ACSL are present in rat liver (61,64), 
these data suggest that in rat hepatocytes, ACSL1, 3, 4 might provide acyl-CoAs for TAG 
and CE synthesis, but not for β-oxidation.  Different ACSL isoforms also respond 
differently to inhibition from TZDs.  At 10 µM TZDs inhibit purified ACSL4 85-95% and 
purified ACSL5 less than 20%, but do not change activities of ACSL1, 3, or 6 (21,51).  
Since TZDs decrease TAG synthesis without affecting PL synthesis in rat primary 
hepatocytes (81), this highly specific inhibition of ACSL4 by TZD suggests that ACSL4 is 
linked to TAG synthesis.  Identification of more specific inhibitors that can exclusively 
inhibit individual isoforms would help us to understand the mechanisms of fatty acid 
channeling. 
 
1.4.2 Different functions of yeast ACSLs 
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    At least four yeast ACSL isoforms (Faap1-4) have been cloned and characterized, with 
distinct substrate preferences and functions (82).  Faa1p prefers C12:0-C16:0, with C14:0 
and C15:0 having the highest activities (83).  Faa2p uses a wide range of fatty acids, 
preferring C9:0-C13:0 whereas Faa3p has a preference for C16 and C18 fatty acids with a 
cis-double bond at C-9-C-10 (83).  Mutation experiments showed that activation of 
exogenous fatty acid occurs through Faa1p and Faa4p, primarily Faa1p (14).  When Faa1p∆ 
and Faa1p∆Faa4p∆ mutant strains are incubated with exogenous oleate, intracellular 
oleoyl-CoAs levels are reduced to < 10% of wild-type levels (14).  Fatty acid incorporation 
into PLs are reduced dramatically in these strains and the cells cannot grow when 
endogenous fatty acid synthesis is inhibited, suggesting Faa1p and Faa4p mediate exogenous 
fatty acid uptake and metabolism (52,82).  Faap2 has been identified as a peroxisomal 
enzyme and proposed to use endogenous medium-chain fatty acids such as C12:0 for 
β-oxidation in peroxisomes (84).  In a yeast strain containing a mutant 
myristoyl-CoA:protein N-myristoyltransferase and thus having a reduced affinity for 
myristoyl-CoA, Faap4 is the only ACSL that is induced during the growth phase.  Deletion 
of Faap4, but not the other three Faap isoforms, severely impairs the colony-forming 
potential of this yeast strain during stationary phase, indicating that Faap4 is critical in 
providing sufficient N-myristoylation for cellular proteins during stationary phase (85).    
 
1.4.3 Gain-of-function and loss-of-function models 
    More direct evidence of fatty acid partitioning by ACSL comes from experiments that 
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overexpress individual ACSL isoforms.  When McArdle-RH7777 rat hepatoma cells are 
infected with adenovirus carrying rat ACSL5 (Ad-ACSL5), overexpression of ACSL5 
increases acyl-CoA synthetase specific activity 2-fold and alters fatty acid partitioning into 
different pathways (22).  Ad-ACSL5 increases exogenous C18:1 (500 µM) incorporation 
into cellular DAG, TAG, and oxidation products 2-fold, 42% and 13%, respectively, without 
affecting synthesis of PL or CE or medium TAG (22).  Overexpression of ACSL5 also 
increases glycerol incorporation into cellular TAG 28% but decreases its incorporation into 
PL 22%, suggesting that ACSL5 provides acyl-CoAs for TAG synthesis through both de 
novo and reacylation pathways, but away from de novo PL synthesis (22).  Further, ACSL5 
overexpression does not affect acetate incorporation into any of these pathways, indicating 
that ACSL5 exclusively partitions exogenously derived fatty acids toward TAG synthesis.   
 
    In a ACSL1 heart-specific transgenic mice line that has 11-fold increase of ACSL1 
protein, heart TAG content increases 12-fold with broad acyl-chain distribution (C14 to C18) 
(86).  These mice also display a 50% increase in choline glycerophospholipids and a 15% 
increase in ethanolamine glycerophospholipids, but no difference in heart CE content or 
β-oxidation (86).  The marked accumulation of TAG increases left-ventricular mass 
developing at 3 weeks of age, concurrent with reduction of systolic function.  These mice 
also display loss of cardiac myocytes and fibrosis replacement, and die prematurely with a 
dilated cardiomyopathy (86), suggesting that lipid accumulation from unbalanced 
metabolism can cause lipotoxicity in the heart, thus linking obesity and development of 
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cardiovascular diseases.  This in vivo overexpression model supports the idea that ACSL1 
facilitates exogenous fatty acid uptake and metabolism towards specific pathways, and the 
idea that individual ACSL might be a potential therapeutic target for diseases such as obesity 
and related metabolic complications.    
     
    Additionally, in a study to examine whether the ACS component of FATP1 functions in 
partitioning fatty acid to acyl-CoA pools for various metabolic pathways, FATP1 upregulates 
de novo TAG synthesis while down-regulating de novo sphingomyelin synthesis in growing 
293 cells (87).   
 
    On the other hand, loss of function of specific ACSL isoforms suggests that they are not 
functionally exchangeable.  As described in Chapter 1.3.5, mutations of ACSL4 in humans 
are linked to nonspecific X-linked mental retardation, despite the presence of other ACSL 
isoforms in brain, suggesting that the role of ACSL4 cannot be replaced.  Heterozygous 
female mice (ACSL4 +/−) have reduced frequency of pregnancy, a high frequency of in utero 
embryonic death, and abnormal uterine morphology during development (88).  Although a 
few hemizygous male mice (ACSL4 −/Y) appear normal and fertile, no homozygous female 
mice (ACSL4 −/−) are born (88), suggesting that ACSL4 deficiency can be lethal in female 
mice.  Female ACSL4 +/− mice also have a marked increase in uterine prostaglandins such 
as PGE2, suggesting that ACSL4 deficiency alters C20:4 metabolism and thus, the 
production of eicosanoids.  
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    With all the evidence supporting the hypothesis of ACSL in fatty acid channeling, the 
challenges we are faced with are to define the individual role of ACSL isoforms in lipid 
metabolism. 
 
1.5 Does ACSL1 channel fatty acid towards triacylglycerol synthesis in liver? 
    The isoform ACSL1 has been studied most extensively among rat ACSL isoforms.  
Several lines of evidence suggest that ACSL1 might be associated with TAG synthesis, 
particularly in adipocytes.  However, its function in liver has remained unclear.  Studies 
with overexpression of ACSL1 or knockdown in liver are lacking. 
 
1.5.1 Potential role of ACSL1 in triacylglycerol synthesis 
    ACSL1 is abundant in tissues with high capacity of TAG synthesis, such as liver and 
adipose tissue (45).  In adipocytes, in addition to plasma membrane and ER, ACSL 1 is 
present on the surface of lipid droplets (89).   
 
    During the differentiation of 3T3-L1 preadipocytes, microsomal ACS activity increases 
100-fold, together with increased activity of three other enzymes in TAG synthesis, GPAT, 
1-acylglycerol-3-phosphate acyltransferase, and diacylglycerol acyltransferase (DGAT) (90).  
Concomitant with TAG accumulation, ACSL1 mRNA increases ~160-fold, whereas other 
isoforms remain unchanged (48,63), indicating that the increase of ACS activity is mainly 
due to the increase of ACSL1.  Moreover, ACSL1 expression is increased by the lipogenic 
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hormone, insulin, but decreased by the lipolytic cytokine, tumor necrosis factor α (91).   
 
    ACSL1 expression is regulated in parallel with the change of TAG synthesis in animal 
models.  In both genetic and acquired obesity, ACSL1 mRNA level and ACS activity 
increases in adipose tissue and liver (67,92,93).  For example, in ventromedial 
hypothalamus – lesioned rats, a model for acquired obesity, ACSL1 mRNA increases in 
adipose tissue before the onset of obesity, suggesting that the rapid induction of ACSL1 and 
other genes contributes to fat accumulation at an early stage (94).  In addition, PPARγ 
agonists, which promote adipogenesis, increase ACSL1 mRNA 7-fold in rat epididymal and 
omental adipose tissues (95).  Conversely, ACSL1 mRNA decreases markedly in primary 
adipocytes isolated from combined epididymal and retroperitoneal fat depots of rats that have 
been starved for 1 d or 3 d (96).  
 
    This evidence, in addition to the observation that overexpression of ACSL1 in NIH 3T3 
fibroblasts and mouse heart increases TAG synthesis, suggests that ACSL1 is linked to 
lipogenic pathways in these cells and tissues.   
 
1.5.2 PPARα regulates ACSL1 via PPRE 
    The function of ACSL1 in liver, however, is more complicated and controversial.  In 
hepatocytes, ACSL1 is mainly located in ER, the site for TAG synthesis, but is not found in 
mitochondria, the site for fatty acid β-oxidation (64,80).  Refeeding rats with a high fat or 
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high sucrose diet after fasting increases hepatic ACSL1 mRNA 7-fold (45) and microsomal 
ACSL1 protein 89% (80), suggesting that ACSL1 might be linked to TAG synthesis in liver.  
However, PPARα ligands such as fenofibrate, which stimulate genes related to fatty acid 
β-oxidation, induce a large increase in both ACSL1 mRNA and ACS activity in liver (97,98).  
Regulation by PPARα is mediated by a PPAR-responsive element (PPRE) in the promoter of 
Acsl1 (99).  In vitro studies also show that fibrates increase ACSL1 mRNA level in a 
dose-dependence pattern in AML-12 mouse hepatocytes and Fa 32 rat hepatocytes (95).  
Overexpression of hepatocyte nuclear factor 4α (HNF-4α) in human hepatoma cells 
increases ACSL1 and PPARα, as well as some enzymes related to fatty acid oxidation (100).  
Taken together, ACSL1 mRNA in liver can be upregulated under conditions when 
β-oxidation is increased.  
 
1.6 Potential acute regulation of long chain acyl-CoA synthetase 
1.6.1 Indirect evidence of acute regulation 
    As the enzyme that catalyzes the requisite initial step for cellular fatty acid metabolism, 
ACSL could be an important point for regulation in the control of lipid metabolism.  
Previous studies provide indirect evidence that ACS activity is regulated acutely.  For 
example, microsomal ACS activity increases 2-fold in isolated rat adipocytes after incubating 
with insulin for only 2 minutes (101).  Lipolytic factors such as norepinephrine, ACTH and 
glucagon decrease ACS activity concomitantly with lipolysis, whereas insulin or 
β-adrenoceptor blocker propranolol reverses the norepinephrine effect rapidly, resulting in 
  27
restoration of ACS activity back to control within 5 min (102).  The dose-response curve for 
inactivation of ACSL by noradrenaline is similar to the curve for stimulation of lipolysis 
(102), indicating ACSL in adipocytes may be regulated in a manner similar to hormone 
sensitive lipase (HSL).  Dibutyryl cAMP decreases ACS activity by 62%, suggesting that 
cAMP-protein kinase A-phosphorylation may play a role in the acute regulation (102).   
 
    Despite the evidence above suggesting that ACS activity may be acutely regulated, 
another study shows that insulin has no effect on ACS activity in the perfused rat liver (103).  
Moreover, the observations of acute regulation were made years before the different ACSL 
isoforms were cloned.  So we do not know which isoform(s) is acutely regulated, if true.  
So far, little has been reported on acute regulation of individual ACSL isoforms.  In one 
study with rat primary adipocytes, a 15 min incubation with insulin increases ACSL specific 
activity in the plasma membrane and vesicular fractions, with unchanged amount of 
associated ACSL1 protein (43), indicating that acute regulation by insulin might change ACS 
activity by mechanisms other than protein expression.  However, since the activity of 
individual ACSL isoforms was not differentiated, we do not know whether the activity 
change was contributed by ACSL1 or other isoforms present in these fractions.  
 
1.6.2 Potential ACSL1 phosphorylation sites prediction 
    The Netphos program (http://www.cbs.dtu.dk/services/NetPhos/) predicts 24 potential 
phosphorylation sites on rat ACSL1, including 9 serine, 7 threonine, and 8 tyrosine residues.  
  28
Among them are two potential serine sites with high prediction scores for protein kinase A 
(PKA), S74 (0.823) and S411 (0.986) (Scheme 1.4).  Sequence comparison between the 
sequence of rat ACSL1 with mouse and human ACSL1 (ClustalW Alignment 
http://www.ebi.ac.uk/clustalw/) shows that these two serine residues and surrounding amino 
acids are highly conserved.  Therefore, if phosphorylation occurs on these serine residues, it 
is possible that the same mechanism might exist in rodents and human.  Additionally, S74 is 
conserved in rat ACSL6, and S411 is conserved in ACSL5 and ACSL6, with identical 
surrounding sequences in the subfamily of ACSL1, 5, and 6, suggesting that these two serine 
sites are important for ACSL function.   
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Scheme 1.4.  Potential phosphorylation sites for protein kinase A (PKA) on long chain 
acyl-CoA synthetase 1.  The Netphos program (http://www.cbs.dtu.dk/services/NetPhos/) 
predicts two potential PKA phosphorylation sites in rat ACSL1.  The two sites, Ser 74 and 
Ser 411 have high predicted scores, and are conserved among rodent and human ACSL1, 
with highly conserved surrounding amino acids (ClustalW alignment 
http://www.ebi.ac.uk/clustalw/).  The scheme shows the approximate positions of the 
potential PKA sites, the ATP/AMP signature motif, and the FACS signature motif in rat 
ACSL1.   
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CHAPTER II 
FUNCTIONS OF RAT ACYL-COA SYNTHETASES IN BACTERIA 
    The five rat ACSL isoforms display different substrate preferences, tissue expression, 
sensitivity to inhibitors and subcellular locations.  We hypothesized that these isoforms were 
functionally specific, rather than being redundant.  To test this hypothesis we transformed 
individual ACSL isoforms into E. coli that contain mutated endogenous ACSL (FadD).  
Since FadD is the only ACSL in E. coli and functions in vectorial acylation for exogenous 
fatty acid (Scheme 2.1 ), E. coli with a mutation in FadD cannot grow on medium with fatty 
acid as the sole energy source.  Transformation of rat ACSL isoforms into E. coli fadD 
addressed the question of whether rat ACSL isoforms differed in their ability to replace the 
single FadD in fatty acid transport and utilization.  An isoform that could replace FadD 
would enable the mutated E. coli to transport exogenous fatty acids, to incorporate fatty acids 
into lipid metabolism, and to grow on medium with fatty acid as the only energy source.
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Scheme 2.1.  E. coli model to study the rat ACSL isoforms.  When E. coli are grown in 
medium with exogenous fatty acids, LCFA is imported by outer membrane protein FadL and 
then esterified by inner membrane ACSL (FadD).  This so called “vectorial acylation” 
associates LCFA uptake with activation.  Fatty acyl-CoA binds to transcription factor FadR 
and releases its repression on the fatty acid degradative genes (fad genes).  Expressed 
enzymes for LCFA degradation uses acyl-CoA to produce acetyl-CoA for β-oxidation to 
provide energy (37).  When fadD is mutated, vectorial acylation is impaired and no 
acyl-CoA binds FadR, which results in inhibition of fad genes and fatty acid oxidation.  
This fadD mutant (fadD) thus cannot grow with LCFA as the sole energy source.  Both wild 
type strain and mutated strain can grow with glucose as energy source because FadD is not 
essential under this condition, thus serving as a positive control.  We use this mutated strain 
as the model to study the differences of rat ACSL isoforms in their ability to replace the 
single FadD in fatty acid transport and utilization.   
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2.1 Manuscript 1: Rat long-chain acyl-CoA synthetase 5, but not 1, 2, 3, or 4 
complements Escherichia coli fadD‡ 
Authors:  Jorge M. Caviglia*, Lei O. Li*§, Shuli Wang, Concetta C. DiRusso, Rosalind A. 
Coleman, Tal M. Lewin 
‡ ACS2 was used instead of ACSL6 before revised nomenclature for ACSL family (50) 
* Authors contributed equally to this work. 
§ Middle initial (O.) is added for all of Lei Li’s journal publications. 
J Biol Chem 2004 Mar 19;279(12):11163-9 
Abstract.  Long-chain fatty acids are converted to acyl-CoAs by acyl-CoA synthetase (fatty 
acid CoA ligase: AMP forming, E.C. 6.2.1.3; ACS).  Escherichia coli has a single ACS, 
FadD, which is essential for growth when fatty acids are the sole carbon and energy source.  
Rodents have five ACS isoforms that differ in substrate specificity, tissue expression and 
subcellular localization, and are believed to channel fatty acids towards distinct metabolic 
pathways.  We expressed rat ACS isoforms 1, 2, 3, 4 and 5 in an E. coli strain that lacked 
FadD.  All rat ACS isoforms were expressed in E. coli fadD or fadDfadR and had ACS 
specific activities that were 1.6- to 20-fold higher than the wild-type control strain expressing 
FadD.  In the fadD background, the rat ACS isoforms 1, 2, 3, 4 and 5 oxidized [14C]oleate at 
5 to 25% of the wild-type levels, but only ACS5 restored growth on oleate as the sole carbon 
source.  To ensure that enzymes of β-oxidation were not limiting, assays of ACS activity, 
β-oxidation, fatty acid transport, and phospholipid synthesis were also examined in a fadD 
fadR strain, thereby eliminating FadR repression of the transporter FadL and the enzymes of 
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β-oxidation. In this strain, fatty acid transport levels were low but detectable for ACS1, 2, 3, 
and 4 and were nearly 50% of wild-type levels for ACS5.  Despite increases in β-oxidation, 
only ACS5 transformants were able to grow on oleate.  These studies show that although 
ACS isoforms 1-4 variably supported moderate transport activity, β-oxidation, and 
phospholipid synthesis, and although their in vitro specific activities were greater than that of 
chromosomally encoded FadD, they were unable to substitute functionally for FadD 
regarding growth.  Thus, membrane composition and protein-protein interactions may be 
critical in reconstituting bacterial ACS function. 
 
Introduction 
    Acyl-CoA synthetase (fatty acid CoA ligase: AMP forming, E.C. 6.2.1.3; ACS)1 
catalyzes the conversion of long chain free fatty acids into their CoA esters, and plays an 
important role in fatty acid metabolism in bacteria, yeast and mammalian cells (4,66).  In 
yeast, the ACS isoforms Faap1 and 4 are required for the utilization of exogenous fatty acids 
for growth and transport (52), and in NIH 3T3 cells, overexpression of mouse ACS1 
increases fatty acid uptake (16).   
 
    The E. coli ACS enzyme FadD and the fatty acid transport protein FadL are essential 
components of a fatty acid uptake system (37).  Because the outer membrane of E. coli 
contains lipopolysaccharide which constitutes a barrier for hydrophobic molecules, fatty 
acids are not able to cross it by diffusion, but require the transport protein FadL.  Protonated 
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fatty acids then cross the bacterial inner membrane in a process favored by the proton 
gradient and are abstracted from the membrane and concomitantly trapped within the cell as 
acyl-CoA esters by the membrane-associated ACS, FadD (37).  FadL-mediated transport 
and the subsequent FadD-mediated formation of acyl-CoA esters is defined as vectorial 
acylation, a process that allows exogenous fatty acids to be used by bacteria as their energy 
source as well as a substrate for phospholipid biosynthesis.  Thus, when no other carbon 
source is available, exogenous fatty acids are converted to acyl-CoA esters which bind to the 
transcription factor FadR and derepress the expression of the fad genes that encode proteins 
responsible for fatty acid transport (FadL), activation (FadD), and β-oxidation (FadA, FadB, 
FadE and FadH) (37).  When alternative sources of carbon are available, bacteria synthesize 
fatty acids as acyl-ACPs which are used for phospholipid synthesis but are not substrates for 
β-oxidation.  Thus acyl-CoA and acyl-ACP constitute independent pools of fatty acids 
destined for different fates. 
 
    Contrasting with the single ACS present in bacteria, eukaryotes express multiple ACS 
isoforms that are not functionally equivalent (66).  Six yeast isoforms ( Faap 1 – 4, Fat1p 
and Fat2p) have been cloned and characterized (82).  Faap1 and Faap4 are essential for the 
utilization of exogenous fatty acids, since faa1∆faa4∆ strains cannot grow when endogenous 
synthesis is inhibited by the fatty acid synthase inhibitor cerulenin unless supplemented with 
14:0, 16:0, or 18:1 (52).  Faap2 activates endogenous medium-chain fatty acids destined for 
β-oxidation in peroxisomes (84), and Faap3 also uses endogenous fatty acids, but their 
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specific fate is uncertain (104).  Fat1p has specificity for very long chain fatty acids (105) 
and is required for efficient fatty acid uptake (23).  
 
    In rats and humans, five long-chain ACS isoforms2 have been cloned (4,66).  These 
isoforms have different substrate preferences, are expressed in different tissues and are 
present in different subcellular locations. The expression of each of the rat isoforms is likely 
to be regulated independently.  For example, ACS1 mRNA in different tissues is variously 
upregulated by PPARα and PPARγ (95,106) and by insulin (107), ACS2 in brain is 
upregulated by PPARβ (62), and ACS4 mRNA is induced by ACTH and by 20:4 and down 
regulated by dexamethasone in steroidogenic tissues (108).  These and other data suggest 
that rat ACS isoforms, like those of yeast, are not redundant, but rather, that they have 
distinct functions, possibly directing fatty acids to different metabolic pathways.  In human 
skin fibroblasts, triacsin C, which inhibits ACS1 and 4 but not ACS5 (21), blocks de novo 
glycerolipid synthesis but does not affect lysophospholipid reacylation (79), suggesting that 
different ACS isoforms generate independent acyl-CoA pools which have specific fates.  In 
similar experiments with rat hepatocytes, thiazolidinediones, which are inhibitors of rat 
ACS4 but not ACS1 or 5 (21), markedly decrease the synthesis of TAG but have less effect 
on β-oxidation (81).  Female mice heterozygous for ACS4 gene inactivation have increased 
production of eicosanoids in uterine tissue and reduced fertility, suggesting that other 
isoforms cannot compensate for even a partial lack of ACS4 (88).  In humans, mutations in 
the FACL4 gene (ACS4 homolog) that inactivate the enzyme are linked to mental retardation 
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(54,109), again suggesting that the unique function of this isoform in brain cannot be 
replaced.   
 
    Expression of rat ACS1 rescues yeast faa1∆ faa4∆ strains and allows growth on a 
fermentable carbon source when cerulenin and exogenous long-chain fatty acids are present 
(52), indicating that a mammalian ACS can functionally substitute in a lower eukaryote.  
Because the long-chain ACSs may have independent functions, we wondered whether they 
would vary in their ability to replace the single ACS in E. coli, FadD, in fatty acid vectorial 
transport and the activation of exogenously provided fatty acids.  To answer this question, 
we transformed rat ACS1-5 into E. coli fadD and measured transport, β-oxidation, lipid 
synthesis, and growth in the presence of oleate as the only source of carbon and energy. 
 
Experimental Procedures 
Construction of recombinant pFLAG-CTC-ACS plasmids.  Plasmids 
pFLAG-CTC-ACS1, -ACS4, and –ACS5 express the ACS isoforms as fusion proteins with a 
C-terminal FLAG epitope, under the control of a tac promoter (21).  In order to obtain 
cDNA clones of ACS2 and ACS3, rat total brain RNA was isolated using Trizol reagent 
(Invitrogen) and cDNAs were synthesized using M-MLV reverse transcriptase (Invitrogen).  
Rat ACS3 (GenBank accession number D30666) (46) was amplified by PCR using the upper 
primer 5’-CTAAGCTTCACATGAATAACCACGTATCTTCAACAC-3’ and the lower 
primer 5’-AAGTCGACTTTTCTTCCGTACATCCGCTCAATG-3’.  The product included 
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the open reading frame flanked by the recognition sequences for HindIII and SalI restriction 
enzymes.  Following digestion with HindIII and SalI, the amplified ACS3 cDNA was 
ligated into the pFLAG-CTC vector to produce pFLAG-CTC-ACS3.  Rat ACS2 (GenBank 
accession number D10041) (49) was amplified by PCR using the upper primer 
5’-ATAAGCTTAAGATGCAGACCCAGGAGATCCTG-3’ and the lower primer 
5’-GTACTCGAGACATGGAGATTGAGTACAGCTCTTCT-3’, and ligated into 
pCR-BluntII-TOPO vector (Invitrogen) according to the manufacturer instructions.  The 
ACS2 cDNA was excised with HindIII and XhoI, and then ligated into the pFLAG-CTC 
vector to  generate pFLAG-CTC-ACS2.  The sequences of ACS2 and 3 were verified by 
automated DNA sequencing (UNC-CH Automated DNA Sequencing Facility). 
 
Strains, transformation and culture conditions.  E. coli strain 
BL21-CodonPlus(DE3)-RIL was obtained from Stratagene and will be referred to as 
BL21(DE3)RIL or wildtype throughout this paper.  A strain containing a fadD deletion was 
generated by P1 transduction of BL21-(DE3)RIL with fadD::kan as described previously (12) 
and is referred to as BL21(DE3)RILfadD.  A spontaneous fadR mutant was obtained by 
plating BL21(DE3)RIL on minimal medium containing decanoate (110).  This mutant, 
BL21(DE3)RILfadR constitutively expresses the fatty acid degradative enzymes (Fad) 
without oleate induction.  It was transduced with a P1 bacteriophage grown on 
BL21(DE3)RILfadD to generate the strain BL21(DE3)RILfadR fadD. Bacteria were 
transformed by the Hanahan protocol (111); strains transformed with pFLAG-CTC vector 
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without an insert were used as control.  For routine culture, liquid Terrific Broth (TB) media 
(Invitrogen) and Luria-Bertani agar (Fisher) plates were used; 50 µg/ml carbenicillin (Life 
Technologies) was added to maintain the plasmids.  Growth in liquid cultures was 
monitored by measuring optical density at 600 nm (OD600).  Frozen stocks were prepared in 
LB media 7% DMSO and stored at -80°C.  
 
Transport assay.  BL21(DE3)RILfadR fadD transformed with pFLAG derivatives of rat 
ACS 1-5 was used to inoculate an overnight culture in TB.  The next morning cells were 
subcultured at 1:100 dilution in the same medium.  When growth reached mid-log phase, 
protein production was induced with 1 mM IPTG for 1 h.  Cells were then harvested by 
centrifugation (3400 x g 15 min at room temperature), rinsed once with M9 medium (112)  
and 0.5% Brij 58, resuspended in one-half volume of the same media containing 100 µg/ml 
chloramphenicol, and starved for 15 minutes at 30ºC.  Fatty acid transport was measured by 
adding 100 µM [3H]potassium oleate (final concentration).  At 0, 2, 4, and 6 min aliquots 
were pipetted onto filter GN-6, washed twice with M9 0.5% Brij 58, air dried and counted 
(113) .   
 
Induction of rat ACSs and fad genes for β-oxidation and lipid synthesis experiments.  
Bacteria were grown overnight in 3 ml of TB media at 37°C with shaking.  The next 
morning the bacteria were harvested by centrifugation and resuspended in Medium E with 
0.01 g/l thiamine (Med EB1), 25 mM potassium acetate, 1 g/l casamino acids.  The cell 
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density was adjusted to OD600 ≈ 0.1 and the bacteria were grown in 250 ml Erlenmeyer flasks 
at 37°C with shaking at 240 rpm.  When the cultures reached mid-log phase (OD600 ≈ 0.5), 
the expression of the recombinant rat ACS isoforms was induced with 1 mM IPTG.  At the 
same time, in the BL21(DE3)RIL and BL21(DE3)RILfadD strains the expression from the 
endogenous fad genes responsible for β-oxidation was induced with 5 mM potassium oleate 
in 0.5% Brij58 (114).  No oleate was necessary for fadR and fadR fadD strains because 
these fadR mutants constitutively express the proteins of the fad regulon.  The cultures were 
allowed to grow for one hour and aliquots were used to measure lipid incorporation.  To 
measure β-oxidation, cells were harvested by centrifugation and washed twice with Med EB1, 
0.5% Brij58, 1 mM IPTG with no carbon source and resuspended in Med EB1, 1 mM IPTG 
0.1 g/l chloramphenicol, bringing the cell concentration to OD600 ≈ 1.  Protein content was 
determined in separate aliquots.  The remaining cultures were further processed to measure 
ACS activity and to perform immunoblot analyses. 
 
β-oxidation assay.  To measure β-oxidation, 2 ml aliquots of the bacterial cultures 
described above were incubated for one hour at 37°C with shaking at 240 rpm with 500 µM 
[14C]oleic acid in 0.5 % Brij58 in rubber-stoppered vials with center wells.  Then, 0.5 ml 5 
N H2SO4 was added to the medium to promote the evolution of [14C]CO2, which was trapped 
in center wells filled with 0.2 ml ethanolamine:ethanol 1:1 (v/v).  After an additional hour 
of shaking, the contents of the center wells were transferred to vials and the [14C]CO2 
produced was measured by scintillation counting (115).  Experiments were performed in 
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triplicate and results are presented as mean ± S.E. of a representative experiment, which was 
repeated two to six times for BL21(DE3)RIL wildtype and fadD strains and twice with fadR 
and fadR fadD strains.  Differences were analyzed by Student’s t test.   
 
Lipid synthesis.  Bacteria were grown to midlog phase and the expression of rat ACS 
isoforms was induced for 1 h as described above.  Then 1 ml of culture was incubated with 
20 µM of [1-14C]oleate (1 µCi) (final concentration) for 30 min at 37°C.  Cultures were then 
chilled on ice and washed three times with PBS buffer containing 0.5% Brij58.  Lipids were 
extracted (116), and [14C]oleate incorporation was measured by scintillation counting.  
Incorporation into phospholipid species was determined by thin layer chromatography in 
CHCl3/ethanol/H2O/triethylamine (30/35/7/35; v/v) using authentic standards (117).   
 
Preparation of bacterial lysate.  Bacterial cultures described above were harvested by 
centrifugation for 10 minutes at 5000 rpm in a Sorval SA-600 rotor at 4°C, and resuspended 
in 10 mM HEPES, pH 7.8, 0.5 mM EDTA buffer.  The bacteria were lysed by sonication on 
ice, with six 10 seconds bursts and 10 second rest intervals using a heat system-ultrasonic 
cell disruptor sonicator (Heat systems-Ultrasonics) at setting 4.  Lysate aliquots were stored 
at -80°C until used for enzyme assay. 
 
ACS activity assay.  ACS activity was measured using 17 to 80 µg of bacterial lysate.  
Assays contained 175 mM Tris-HCl pH 7.4, 8 mM MgCl2, 5 mM DTT, 10 mM ATP, 0.25 
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mM CoA and 50 µM [14C]palmitic acid (New England Nuclear) in 0.5 mM Triton X-100, 
0.01 mM EDTA in a total volume of 200 µl.  Assays were performed at 37°C for 5 min with 
shaking.  The reaction was started by adding lysate protein and terminated by adding 1 ml 
Dole’s reagent (isopropanol:heptane:1 M H2SO4 80:20:2).  The unreacted free fatty acid 
was removed with two 2-ml heptane washes, and the labeled acyl-CoA produced by the 
reaction was measured by scintillation counting (118).  The assays measured initial rates. 
 
Immunoblot analysis.  Proteins from the bacterial lysate (1 or 2 µg) were resolved on a 10 
% polyacrylamide gel containing 1% SDS and transferred onto polyvinylidene difluoride 
membranes (BioRad).  Immunoreactive bands were detected by incubating the membranes 
with anti-FLAG M2 monoclonal antibody (Sigma), horseradish peroxidase-conjugated goat 
anti-mouse IgG (Pierce) and SuperSignal West Pico Chemiluminescent Reagent (Pierce). 
 
Growth complementation of fadD deletion.  Bacteria were transformed with plasmids 
containing different isoforms of rat ACS or no insert.  These were examined for their ability 
to grow on oleate as the sole energy and carbon source.  Transformants were streaked on 
Med EB1 agar plates supplemented with 50 µg/ml carbenicillin, 5 mM potassium oleate 
solubilized in 0.5 % Brij 58 (final concentration), and different concentrations of IPTG 
(0.005, 0.01, 0.02, 0.05, 0.1, 0.2 and 0.5 mM).  Control plates were supplemented with 
25 mM glucose and the appropriate concentration of IPTG.  The plates were incubated at 
37°C and growth was checked daily for seven days. 
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Other methods.  Protein content was measured using bovine serum albumin (BSA) as the 
standard (119).  
 
RESULTS 
Rat ACS isoforms 1-5 are expressed and active in BL21(DE3)RILfadD.  In order to 
determine whether rat ACS isoforms can functionally replace FadD, the sole ACS enzyme in 
bacteria, the coding region of fadD was deleted in BL21(DE3)RIL to generate strain 
BL21(DE3)RILfadD.  The fadD strain had ACS activity levels indistinguishable from 
background and was unable to grow when oleate was the sole energy and carbon source (Fig. 
2.2, Table 2.1).  BL21(DE3)RILfadD was transformed with the expression vector 
pFLAG-CTC-ACS1, 2, 3, 4, or 5 or with the empty vector as a control. The rat ACS isoforms 
were each expressed as a fusion protein with a C-terminal FLAG epitope.  The FLAG 
epitope does not interfere with ACS activity or kinetic properties (21).   
 
    All five ACS isoforms were expressed in BL21(DE3)RILfadD, with ACS1 and 4 
exhibiting the greatest expression and ACS5 the least (Fig. 2.1A).  All isoforms exhibited 
ACS activity (Fig. 2.2A). In each case, the specific activity was at least 1.6-fold higher 
(ACS5) and as much as 20-fold higher (ACS4) than the specific activity of the bacterial 
enzyme FadD in the wildtype control strain containing the empty vector.  Further, the 
correlation was poor between expressed protein and enzyme activity.  Although the 
expression of ACS4 protein was not substantially different from that of ACS1, ACS4 specific  
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Table 2.1.  Only rat ACS5 complements absence of FadD. 
 
Strain Vector EB1 Media 
  25 mM Glucose 5 mM oleate 
BL21(DE3)RIL Empty +++ +++ 
Empty +++ - 
ACS1 +++ - 
ACS2 +++ - 
ACS3 +++ - 
ACS4 +++ - 
 
 
fadD 
ACS5 +++ ++ 
fadR Empty +++ +++ 
Empty +++ - 
ACS1 +++ - 
ACS2 +++ - 
ACS3 +++ - 
ACS4 +++ - 
 
 
fadD fadR 
ACS5 +++ ++ 
 
BL21(DE3)RIL and BL21(DE3)RILfadR containing the empty vector (EV) or 
BL21(DE3)RILfadD and fadR fadD containing vectors expressing ACS1, 2, 3, 4 or 5  were 
streaked on medium EB1 agar plates supplemented with 5 mM oleate in 0.5 % Brij58 as the 
sole energy and carbon source. EB1 agar plates containing 25 mM glucose were used as 
controls. The plates were incubated at 37°C and checked daily.  This experiment was 
repeated 6 to 11 times with both carbon sources and IPTG concentrations of 0.005 to 0.5 mM.  
+++, WT growth; ++, intermediate growth; -, no growth. 
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Figure 2.1.  Rat ACS isoforms 1-5 are expressed in E. coli fadD.  BL21(DE3)RILfadD 
(A) or BL21(DE3)RILfadR fadD (B) transformed with different ACS isoforms was grown as 
described under Experimental Procedures.  Expression was induced for 1 h with 1 mM 
IPTG.  Lysates were prepared and 1 µg (A) or 2 µg (B) of protein was resolved by 10 % 
SDS-PAGE and subjected to immunoblot analysis using M2 anti-FLAG antibody. Exposure 
time was 2 seconds except for ACS5 which was exposed for 20 sec (A) or 30 min (B). The 
experiment was repeated twice.  Representative results are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Rat ACS isoforms 1-5 expressed in E. coli fad D are active.  
BL21(DE3)RILfadD (A) or BL21(DE3)RILfadR fadD (B) transformed with the empty 
vector (EV) or in which rat ACS expression was induced for 1 h with 1 mM IPTG was used 
to prepare lysates as described in the Experimental Procedures. ACS specific activity was 
assayed with 14 to 70 µg protein.  BL21(DE3)RIL (WT) (A) and BL21(DE3)RILfadR (B) 
strains transformed with the EV were used as controls.  Data are presented as means ±SE (n 
≥ 3). 
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activity was 8-fold higher than that of ACS1, perhaps because ACS4 is a peripheral 
membrane protein like FadD.  In contrast, ACS1 and ACS5 (and probably ACS2 and 3) are 
integral membrane proteins whose activity might be negatively affected by the composition 
of the bacterial membrane, which differs considerably from the phospholipid composition of 
mammalian membranes (120).  
 
Rat ACS isoforms 1-5 activate exogenous fatty acids for β-oxidation.  When 
carbohydrate is not available, E. coli can import and activate exogenous fatty acids to 
acyl-CoA esters that are then oxidized to provide energy.  BL21(DE3)RILfadD expressing 
each of the rat ACS isoforms was studied to determine whether these rat ACS isoforms 
would be able to supply fatty acyl-CoA for β-oxidation in the absence of FadD (Fig. 2.3A).  
As expected, BL21(DE3)RILfadD transformed with the empty vector was unable to oxidize 
exogenous oleate.  However, transformation with rat ACS isoforms 1, 2, 3, 4, or 5 allowed 
some β-oxidation to occur, indicating that each of the rat ACS isoforms partially replaced 
FadD for this function.  There was no correlation between in vitro specific activities of the 
ACS isoform and the rates of in vivo β-oxidation.  Despite ACS activities that were 1.6-fold 
to 20-fold higher than that of the control BL21(DE3)RIL which contains active FadD (Fig. 
2.2), the relative rates of β-oxidation ([14C]CO2 produced/ACS activity) were 0.2 to 7.5% of 
those observed in the wild-type strain (Fig. 2.3B).  Thus, although the ACS isoforms were 
able to catalyze the formation of acyl-CoAs in vitro, they either did not form acyl-CoAs in  
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Figure 2.3.  Rat ACS isoforms 1-5 partially restore β-oxidation in E. coli fad D.  
BL21(DE3)RILfadD (A, B) or BL21(DE3)RILfadR fadD (C, D) were transformed with the 
empty vector (EV) or with the ACS isoforms. BL21(DE3)RIL (WT) (A, B) and 
BL21(DE3)RILfadR (C, D) strains transformed with the EV were used as controls.  ACS 
expression was induced for 1 h with 1 mM IPTG.    A and B: β-oxidation was measured 
using 0.5 mM [14C]oleic acid for 1 h at 37°C as described in Experimental Procedures. 
Experiments were performed in triplicate.  The mean ± S.E. of a representative experiment, 
repeated two to six times, is plotted. C and D: Relative β-oxidation was calculated ([14C]CO2 
produced/ACS activity) and normalized (WT and fadR controls set at 1). 
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vivo, the acyl-CoAs formed were not accessible to the β-oxidation enzymes, or the activities 
of the β-oxidation enzymes were limiting due to the presence of FadR.    
 
    β-oxidation by E. coli requires expression of the fad genes encoding proteins that 
mediate transport (FadL), activation (FadD), and β-oxidation of exogenous fatty acids (FadA, 
FadB, FadE, and FadH) (114,121).  When carbohydrate is present, the transcription factor 
FadR represses the expression of these proteins.  If long-chain fatty acids are provided as 
the sole carbon and energy source in the culture media, however, the resulting acyl-CoAs 
produced by the activity of FadD bind to FadR and regulate FadR activity (110) by 
promoting the dissociation of FadR from the promoter region of the genes of the fad regulon, 
thereby inducing their expression (122).  If the rat ACSs were not as efficient as FadD in 
providing the long-chain acyl-CoA ligand for FadR, the fad genes might be expressed at low 
levels and limit β-oxidation.  To rule out this possibility, we generated BL21(DE3)RILfadR 
and fadR fadD strains.  These strains have a mutation in the fadR gene that leads to 
constitutive expression of FadL and the β-oxidation enzymes, independent of the presence of 
acyl-CoA.  Expression of the ACS isoforms and their activities in the fadD fadR strain were 
similar to that shown for BL21(DE3)RILfadD (Figs. 2.1B, 2.2B).  As expected, β-oxidation 
in BL21(DE3)RILfadR was 3.7-fold higher than observed in the wildtype strain (Compare 
the first bars in Fig. 2.3A and 2.3C).  However, the rescue of fadR fadD by the five rat ACS 
isoforms was still only partial (Fig. 2.3C); values for relative β-oxidation remained low for 
ACS 1-4 at 0.6 to 16% of the positive control BL21(DE3)RILfadR (Fig 2.3D).  In contrast, 
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relative β-oxidation for fadDfadR bacteria expressing ACS5 was 55% of the fadR control. 
The lower efficiency of rat ACS isoforms 1-4 was not due to low expression of FadL or 
limiting enzymes of β-oxidation.  In both the fadD (Fig. 2.3B) and fadD fadR (Fig. 2.3D) 
strains, ACS5 had the highest rate of β-oxidation relative to expression of activity. 
 
Rat ACS isoforms 1-5 partially restore fatty acid transport in BL21(DE3)RILfadR fadD.  
FadD and FadL comprise the E. coli fatty acid import system that pairs fatty acid transport 
and acylation (37).  To determine whether rat ACS isoforms can replace FadD functionally 
in this import system, oleate transport was measured in BL21(DE3)RILfadR fadD expressing 
each of the five rat ACS isoforms. Transport was defined as 3[H]-oleate incorporation into 
cells in a traditional filtration assay (see Experimental Procedures).  While transport cannot 
be distinguished from metabolic use in this assay, experiments were performed during a 4 
minute period in which the data points are linear and dependent upon both the transporter 
FadL and an acyl-CoA synthetase, generally bacterial FadD.  In the absence of FadD, 
[3H]-oleate import into cells was minimal, reflecting the importance of ACS for this process 
(Fig. 2.4A).  Expression of rat ACS isoforms increased fatty acid transport with respect to 
the negative control harboring the empty vector (Fig. 2.4A).  Compared with the transport 
activity of wild type E. coli (1000 pmol/min/mg protein) (113), the relative transport ranged 
from 0.02% (ACS4) to 12% (ACS5) (Fig. 2.4B).  Thus, relative to specific activity, the 
amount of transport was greatest for ACS5.  Although ACS3 protein expression was also 
low (Fig. 2.1B), its ability to promote fatty acid transport was equivalent to that of ACS1 and 
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2; thus, toxicity from protein overexpression itself cannot explain these results.  
 
Rat ACS isoforms 1-5 activate fatty acids for lipid synthesis.  Vectorial acylation by 
FadL and FadD allows E. coli to use exogenous fatty acids for phospholipid synthesis (121).  
To study the ability of the rat ACS isoforms to substitute for FadD in this process, we 
incubated BL21(DE3)RILfadR and BL21(DE3)RILfadDfadR with [14C]oleate and measured 
label incorporation into lipid.  When FadD was absent, the incorporation of exogenous fatty 
acid into phospholipid was negligible (Fig. 2.5A).  The residual incorporation probably 
reflects [14C]oleate incorporation into PE by the acyl-ACP synthetase/2-acyl-GPE 
acyltransferase system (123).  Expression of the rat ACS isoforms significantly increased 
the incorporation of [14C]oleate into phospholipid compared to the vector control (Fig. 2.5A), 
reaching 10 to 41 % of the values for the control strain BL21(DE3)RILfadR during the 30 
min incubation. When expressed relative to activity, ACS5 substituted most effectively (85%) 
and ACS4 least (1%) (Fig. 2.5B).  The percent of [14C]oleate incorporated into different 
phospholipid species was similar for each of the ACS isoforms (data not shown).  Thus, all 
five rat ACS isoforms could partially replace FadD in providing acyl-CoA for phospholipid 
synthesis, although each was less efficient than the endogenous bacterial enzyme. 
 
Only ACS5 supports the growth of E. coli fadD mutants on fatty acid.  Growth of E. 
coli when long-chain fatty acids are its sole energy and carbon source requires FadD to 
activate fatty acids used for both β-oxidation and for the synthesis of membrane  
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Figure 2.4.  Rat ACS isoforms 1-5 partially restore fatty acid transport in E. coli fadR 
fadD.  A: BL21(DE3)RILfadR fadD transformed with rat ACS isoforms 1-5 or empty vector 
(EV) were grown to mid-log phase in LB media.  Expression of rat ACSs was induced with 
1 mM IPTG for 1 h and fatty acid transport was measured by adding 100 µM [3H]oleate as 
described in Experimental Procedures.  Results represent averages of two independent 
experiments, each performed in triplicate and plotted as the mean ± S.E. B: Relative transport 
was calculated ([3H]oleate transported/ACS activity) and normalized (fadR control set at 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  Lipid synthesis is partially restored by rat ACS isoforms 1-5.  A: 
BL21(DE3)RILfadR was transformed with empty vector (EV).  BL21(DE3)RILfadR fadD 
was transformed with EV or with ACS isoforms.  ACS expression was induced for 1 h with 
1 mM IPTG.  Incorporation of fatty acid into phospholipid was then measured with 20 µM 
[14C]oleic acid for 30 min at 37°C as described in Experimental Procedures.  Experiments 
were performed in triplicate.  The mean ± S.E. of a representative experiment, repeated two 
times, is plotted. B: Relative oleate incorporation into phospholipids was calculated 
([14C]oleate incorporated/ACS activity) and normalized (fadR control set at 1). 
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phospholipids.  To determine whether the low rates of transport, β-oxidation and 
phospholipid synthesis observed with the rat ACSs were sufficient for growth, bacteria were 
streaked on medium EB1 agar plates supplemented with 5 mM oleate in 0.5 % Brij58.  
Plates containing 25 mM glucose were used as controls.  As expected, BL21(DE3)RILfadD 
transformed with the empty vector was unable to grow on oleate (Table 2.1).  
BL21(DE3)RILfadD transformed with rat ACS5 grew on oleate, although growth was slower 
than for the wildtype strain BL21(DE3)RIL.  Bacteria lacking fadD but expressing ACS1, 2, 
3, or 4, however, did not grow on EB1 plus oleate.  BL21(DE3)RILfadD transformed with 
either empty vector or the rat ACS isoforms grew in media that contained glucose, indicating 
that lack of growth on oleate was due to the unavailability of a usable carbon and energy 
source.  These experiments were repeated using BL21(DE3)RILfadR and 
BL21(DE3)RILfadD fadR with comparable results (Table 2.1). 
 
Discussion 
    It has become increasingly apparent that the presence of multiple homologs of an 
enzyme may permit them to perform non-overlapping functions and that the ability of a 
specific mammalian enzyme involved in lipid biosynthesis to complement a defective 
bacterial or yeast gene may provide critical clues about the function or active site of the 
mammalian ortholog.  For example, complementation of the yeast faa1∆faa4∆ strain by rat 
ACS1 showed the ability of this ACS isoform to activate exogenously provided 14:0 and 
16:0 for incorporation into neutral lipid and phospholipid (52).  Further, the triacsin C 
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sensitivity of both Faa4p and ACS1 suggested functional analogy.  Therefore, we attempted 
to determine whether any or all of the rat ACS isoforms could complement E. coli FadD.  
FadD contains the AMP/ATP consensus binding site and the putative fatty acid binding site 
(55) present in the luciferase/ACS superfamily and its amino acids show considerable 
similarity to those of the rat ACSs.  Clustal W (http://www.ebi.ac.uk/clustalw/) analysis 
shows that the rat ACS isoforms most similar to FadD are 1, 2, and 5 with 143, 132, and 131 
identical amino acids, respectively, and that ACS3 and 4 are least similar with only 115 and 
119 identical amino acids, respectively.  LALIGN analysis (124) showed no regions of 
similarity that were uniquely specific to ACS5 and FadD, nor did ACS3, which was 
functionally the least active, have unique differences with FadD. 
 
    Except for ACS4 (65), the rat ACSs are, or are predicted to be, integral membrane 
proteins that have active sites facing the cytosol (125).  Like FadD, the ACSs use a broad 
range of fatty acid substrates from 10 to 22 carbons, but they are differentially inhibited by 
triacsin C and thiazolidinediones and are believed to link acyl-CoAs to different and distinct 
fates within mammalian cells (66).  For example, rat liver ACS1 and 4 are present on 
endoplasmic reticulum and the related mitochondrial associated membrane (64), and in NIH 
3T3 cells ACS1 is located at the plasma membrane (16).  In addition, the fungal metabolite 
triacsin C inhibits recombinant ACS1 and 4 (21), and in human fibroblasts and HepG2 
human hepatoma cells, triacsin inhibits triacylglycerol synthesis and de novo synthesis of 
phospholipids from glycerol-3-phosphate (79,126).  Taken together, these data suggest that 
  53
ACS1 and 4 provide acyl-CoAs for glycerolipid biosynthesis.  Conversely, ACS5 is present 
on mitochondrial membranes and is not inhibited by triacsin C (21,64), suggesting that ACS5 
might play a role in β-oxidation.  ACS2 and 3 have not been extensively studied. 
 
    Bacteria synthesize fatty acids as acyl-ACPs that are used primarily for the biogenesis 
of phospholipids, but cannot be used as substrates for β-oxidation.  In contrast, exogenous 
fatty acids are converted by FadD to acyl-CoAs, which are primarily substrates for 
β-oxidation and, to a minor extent, can be used for phospholipid synthesis (2% activity of 
acyl-ACP pathway). Because mammalian ACS isoforms appear to be linked to specific 
pathways that use acyl-CoAs, we wondered whether they would vary in their ability to 
substitute for FadD in providing acyl-CoAs for β-oxidation and phospholipid synthesis. 
 
    We found that rat ACS5, but not ACS1, 2, 3, or 4, was able to complement E. coli fadD 
functionally to allow growth on oleate as the sole carbon source.  Whereas all the rat ACS 
isoforms exhibited some ability to allow fatty acid transport, β-oxidation, and phospholipid 
synthesis, each of these actions was minimal for ACS1, 2, 3, or 4.  It should be noted that 
fatty acid transport, phospholipid synthesis and β-oxidation were measured in assays of 2-6, 
30, and 60 min, respectively.  In contrast, complementation for growth requires sustained 
energy production and phospholipid synthesis from exogenous fatty acids sufficient for 
bacterial doubling over about 70-140 generations (24-48 h).  The differences we observed 
are particularly striking when viewed relative to ACS activity.  The most divergent pair, 
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ACS4 and ACS5 showed large differences in β-oxidation, oleate transport, and oleate 
incorporation into phospholipids relative to activity. 
 
    Our data are limited by differences in ACS protein expression and relative differences in 
enzyme activity.  It is unclear why expression was excellent for ACS1, 2, 3, and 4 and poor 
for ACS5 in both bacterial strains, and why specific activity relative to expressed protein was 
excellent for ACS5, moderate for ACS4, and poor for ACS1, 2, and 3.   
 
    Why then were four of the rat ACS isoforms functionally ineffective in E. coli?  It may 
be that FadD normally interacts with other proteins.  These could be related to fatty acid 
transport across the bacterial membrane or in pathways of β-oxidation or glycerolipid 
synthesis.  Such protein-protein interactions have not been reported in E. coli lipid 
metabolic pathways, although it has been proposed that mammalian cells channel acyl-CoAs 
towards distinct fates (66).  Although FadD could interact directly with bacterial enzymes of 
β-oxidation, such interactions would not be possible for the mammalian ACSs, whose active 
sites face the cytosol (125) rather than the site of fatty acid oxidation within peroxisomes or 
the mitochondrial matrix.   
 
    On the other hand, FadD is thought to “abstract” fatty acids from the inner membrane 
after their transport through the cell wall by FadL.  Unlike most of the rat ACSs, FadD is a 
soluble protein that is activated upon movement to the bacterial membrane (10).  The 
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mammalian ACSs, which would be present in the bacterial membrane (21), should have been 
able to function similarly in a transport assay.  Except for ACS4, the ACSs are integral 
membrane proteins, and ACS1, 2, and 3 would interact in E. coli in a phospholipid milieu 
very different from the one they would encounter in a mammalian cell.  ACS5, however, is 
positioned on the outer mitochondrial membrane which, like bacterial membranes, contains 
cardiolipin (127).  No studies have been performed on the possible cardiolipin dependence 
of ACS5.  If, however, the E. coli membrane composition altered the transmembrane or 
activating domains of the ACSs such that catalysis was poor, a false estimate of activity may 
have been obtained during an in vitro measurement in the presence of detergent.  
Alternatively, the mammalian ACSs might require post-translational modifications that are 
critical for their in vivo function.   
 
    Another possibility is that over-expression of the rat ACSs was toxic to the bacteria and 
that ACS5 supported growth only because less ACS protein was expressed.  Certainly the 
rates of growth on oleate were markedly decreased in the bacteria expressing the rat enzymes.  
However, if the amount of protein expressed was the problem, growth should also have been 
poor on minimal glucose plates containing the inducer IPTG.   The high expression of 
exogenous proteins in bacteria growing in a minimal media might also have diverted limited 
substrates like amino acids and ATP, thereby compromising the synthesis of other proteins 
that decrease the growth rate, but growth remained poor, even when low IPTG concentrations 
were used to decrease the amount of protein expressed.  Further, when we repeated the 
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studies of the ACSs in a FadR mutant to ensure that FadL and enzymes of β-oxidation were 
not limiting and that ATP and amino acids were not being diverted, growth did not improve 
despite the expected 3.7-fold increase in β-oxidation.    
 
    In complementation experiments with both the BL21(DE3)RILfadD and fadD fadR 
strains, ACS5 consistently supported growth in oleate, whereas ACS isoforms 1-4 were 
unable to substitute for a lack of FadD.  These studies show that although ACS isoforms 1-4 
variably exhibited moderate transport activity, β-oxidation, and phospholipid synthesis, and 
although their in vivo specific activities were greater than that of FadD, they were unable to 
substitute functionally for FadD regarding growth.  ACS5 consistently showed the highest 
relative rates of β-oxidation, fatty acid transport, and oleate incorporation into phospholipids.  
Thus, the membrane composition and protein-protein interactions may be critical in 
reconstituting bacterial ACS function.
CHAPTER III 
THE ROLE OF RAT ACYL-COA SYNTHETASE 1 IN FATTY ACID CHANNELING 
IN RAT PRIMARY HEPATOCYTES 
    The work presented in this chapter focuses on the role of rat ACSL1 in fatty acid 
channeling in hepatocytes.  Although studies suggest that ACSL1 is important for TAG 
synthesis in adipocytes and fibroblasts, conflicting data exist concerning the function of 
ACSL1 in liver.  Upregulation of ACSL1 in liver is shown under both lipogenic and 
oxidative conditions.  All the previous studies focused on the subcellular locations, inhibitor 
effects, expression of mRNA or protein of ACSL1, but no study has been conducted on the 
role of ACSL1 by directly measuring metabolism change imposed by ACSL1.  In the 
current work, we overexpressed rat ACSL1 in rat primary hepatocytes and examined its 
effects on fatty acid channeling (Scheme 3.1).  Consistent with our hypothesis that ACSL 
provides fatty acyl-CoAs to specific downstream pathways, our data showed that 
adenovirus-mediated overexpression of rat ACSL1 channeled oleate toward some specific 
pathways and away from others.  In contrast to overexpression studies of ACSL1 in other 
cell types, overexpressed ACSL1 in hepatocytes increased oleate incorporation into DAG and 
PL, but not TAG, suggesting that the function of ACSL1 might be tissue-specific.
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Scheme 3.1.   Experiment outline of rat ACSL1 overexpression on lipid metabolism.  The 
effects of overexpressed ACSL1 is examined on A) 3 h substrates incorporation and on B) 
prelabeled substrates recycling by pulse-chase experiments.  Rat primary hepatocytes were 
infected with adenovirus carrying either ACSL1 or GFP (control) and labeled with 
[14C]oleate, [3H]glycerol, or [14C]acetate for 3 h.  Lipids were extracted from cell and 
medium samples, and oxidation products were collected.  Labeled lipids were quantified 
after separating by thin layer chromatography.  For recycling study in pulse-chase 
experiment, radio label was removed after 3 h labeling, turnover of cellular lipids was 
examined by measuring the remaining label in different lipids species after a 14 h chase.   
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3.1 Manuscript 1: Overexpression of rat long chain acyl-CoA synthetase 1 alters fatty 
acid metabolism in rat primary Hepatocytes 
Authors:  Lei O. Li, Douglas G. Mashek, Jie An, Scott D. Doughman, Christopher B. 
Newgard, and Rosalind A. Coleman 
J Biol Chem 2006 (under revision) 
Abstract.  Long chain acyl-CoA synthetases (ACSL) activate fatty acids (FA) and provide 
substrates for both anabolic and catabolic pathways.  We have hypothesized that each of the 
five ACSL isoforms partitions fatty acid (FA) towards specific downstream pathways.  
ACSL1 mRNA is increased in cells under both lipogenic and oxidative conditions.  To 
elucidate the role of ACSL1 in hepatic lipid metabolism, we overexpressed an ACSL1 
adenovirus construct (Ad-ACSL1) in rat primary hepatocytes.  Ad-ACSL1, located on the 
endoplasmic reticulum but not on mitochondria or plasma membrane, increased ACS specific 
activity 3.7-fold 24 h after infection.  With 100 or 750 µM [1-14C]oleate, Ad-ACSL1 
increased oleate incorporation into diacylglycerol and phospholipids, particularly 
phosphatidylethanolamine and phosphatidylinositol, and decreased incorporation into 
cholesterol esters and secreted triacylglycerol.  Ad-ACSL1 did not alter oleate incorporation 
into triacylglycerol, β-oxidation products, or the total amount of FA metabolized.  To 
examine the effects of Ad-ACSL1 on lipid turnover, we performed pulse-chase experiments.  
In Ad-ACSL1 cells, more labeled triacylglycerol and phospholipid, but less labeled 
diacylglycerol remained, suggesting that ACSL1 increased reacylation of hydrolyzed oleate 
derived from triacylglycerol and diacylglycerol.  In addition, less hydrolyzed oleate was 
  60
used for cholesterol ester synthesis and β-oxidation.  The increase in [1,2,3-3H]glycerol 
incorporation into diacylglycerol and phospholipid was similar to the increase with 
[14C]oleate labeling.  Labeling Ad-ACSL1 cells with [14C]acetate increased triacylglycerol 
synthesis, but did not channel endogenous FA away from cholesterol ester synthesis.  Thus, 
consistent with the hypothesis that individual ACSLs partition FA, Ad-ACSL1 increased FA 
reacylation and channeled FA towards diacylglycerol and phospholipid synthesis and away 
from cholesterol ester synthesis. 
 
INTRODUCTION   
    Long-chain acyl-CoA synthetases (ACSL) catalyze the first step in FA metabolism by 
converting long-chain FA into acyl-CoA thioesters.  Acyl-CoAs enter both anabolic and 
catabolic pathways (4), and the disturbance of these pathways is linked to disorders such as 
hepatic steatosis, hyperlipidemia, and insulin resistance.  Five ACSL isoforms, each the 
product of a separate gene, have been cloned and characterized in mammals (44,50).  Even 
though individual ACSL isoforms have different substrate preferences, enzyme kinetics, and 
cellular and subcellular locations, and are regulated uniquely (21,51,66), the significance of 
this diversity is unknown.  We hypothesized that instead of being redundant, individual 
ACSL isoforms might channel FA into distinct metabolic pathways.   
 
    Evidence for the importance of ACSL in FA channeling comes from studies with triacsin 
C, an inhibitor of recombinant ACSL1, 3 and 4, but not ACSL5 or 6 (21,51).  For example, 
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in hepatocytes in which ACSL1, 3, 4 and 5 are abundant, triacsin C inhibits TAG synthesis 
70% but inhibits oleate incorporation into phospholipids and β-oxidation only 34% (80).  
More direct evidence comes from studies that overexpress individual ACSL isoforms.  In 
ACSL1 heart-specific transgenic mice, TAG and PL accumulate in heart muscle in the 
absence of changes in CE or β-oxidation (86), and when ACSL5 is overexpressed in rat 
hepatoma McArdle-RH777 cells, it partitions exogenously derived FA towards TAG 
synthesis and storage, but not towards PL or CE synthesis (22).  However, the exact 
function of other ACSL isoforms in liver remains largely unexplored, in part because we lack 
inhibitors that can exclusively inhibit one isoform without affecting others.  
 
    Although studies suggest that ACSL1 is important for TAG synthesis in adipocytes and 
fibroblasts (66,128), conflicting data exist concerning the function of ACSL1 in liver.  
Supporting a role for ACSL1 in TAG synthesis is its location in the ER and 
mitochondria-associated membrane, which are sites of TAG synthesis, and its absence from 
mitochondria, the major site of FA β-oxidation (64).  Further, ACSL1 mRNA is induced 
when previously fasted rats are refed with a high fat or high sucrose diet that favors 
lipogenesis (45,129), and hepatic ACS specific activity and ACSL1 mRNA is enhanced in 
obese and hypertriglyceridemic rats that have fatty livers (92,93).  On the other hand, in 
support of a role for ACSL1 in providing FA for β-oxidation are data showing that PPARα 
agonists, which upregulate genes for both FA β-oxidation and de novo FA synthesis (130), 
increase total ACS activity in rat liver (97) and ACSL1 mRNA expression in rat liver (97) 
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and in the rat liver-derived cell line AML-12 (95).  This upregulated transcription is 
mediated by a PPAR-responsive element in the promoter of the Acsl1 gene (99).     
 
    To elucidate the specific role of ACSL1 in hepatic FA metabolism, we overexpressed rat 
ACSL1 in rat primary hepatocytes.  We hypothesized that ACSL1 would channel FA 
towards some specific lipid metabolic pathways and away from others. 
 
EXPERIMENTAL PROCEDURES 
Materials. DNA restriction endonucleases and ligase for recombinant adenovirus 
construction were from New England Biolabs.  HEK-293 and CHO cells were from the 
American Type Culture Collection.  MEM, nonessential amino acids (NEAA), FBS and 
tissue culture dishes were from GIBCO-BRL Life Technologies.  Rat-tail collagen I was 
from Collaborative Biomedical Products.  Silica gel G plates were from Whatman (cat. 
4865-821).  [1-14C]acetate, [1,2,3-3H]glycerol and [1-14C]oleate were obtained from 
PerkinElmer Life Sciences and [14C]palmitate was from New England Nuclear.  Lipid 
standards were from Sigma and Avanti Polar Lipids.  Polyacrylamide stock was from 
National Diagnostics.  Lab-Tek™ II Chamber Slides™ were from NUNC.  RNeasy kit 
was from Qiagen.  Chemicals were from Sigma-Aldrich unless otherwise indicated.   
 
Construction of pACCMV-ACSL1FLAG adenovirus.  A full-length rat ACSL1 cDNA 
with a C-terminal FLAG epitope (DYKDDDDK) was subcloned from a previously 
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constructed pFLAG-CTC plasmid (21) into a shuttle vector, pACCMVpLpA at the Bam HI 
and Sal I sites.  Expression of the inserted ACSL1FLAG cDNA is driven by the 
cytomegalovirus promoter.  The inserted ACSL1FLAG in the pACCMV-ACSL1FLAG 
construct was verified by restriction enzyme analysis and confirmed by DNA sequencing at 
the UNC DNA sequencing facility.  Expression and activity of the pACCMV-ACSL1FLAG 
construct were confirmed by transient transfection into CHO cells for 24 h, followed by ACS 
activity assay and anti-FLAG Western blot.  The pACCMV-ACSL1FLAG construct was 
cotransfected with an adenoviral DNA, pJM17, into HEK293 cells for homologous 
recombination to form recombinant adenovirus carrying ACSL1FLAG cDNA (Ad-ACSL1) 
(131).  After plaque purification, virions were further purified and amplified by the UNC 
Vector Core Facility.  A virus containing a green fluorescent protein (GFP) gene under 
control of the cytomegalovirus promoter (Ad-GFP) was used for control infections (22). 
 
Hepatocyte isolation and adenovirus infection.  Animal protocols were approved by the 
UNC Institutional Animal Care and Use Committee.  Male Wistar rats (250-300 g) were 
housed in a 12:12-h light-dark cycle and were allowed free access to food (Prolab® 
Rat/Mouse/Hamster 3000 diet, Labdiet) before hepatocyte isolation.  Primary hepatocytes 
were isolated by collagenase perfusion by the UNC Cellular Metabolism and Transport Core.   
Cell viability, determined by trypan blue exclusion, exceeded 90%.  Hepatocytes were 
seeded at a density of 1.5 x 106 cells per 60 mm or 4.5 x 106 cells per 100 mm 
collagen-coated dish in MEM supplemented with 10% FBS (v/v), 50 U/ml penicillin, and 50 
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mg/ml streptomycin (132).  After cells attached (4-5 h), recombinant adenoviruses (Ad-GFP 
or Ad-ACSL1) were added for 2 h at 37oC in serum-free MEM.  Infection medium was 
removed and replaced by MEM containing 10% FBS, 10 nM dexamethasone, and 0.1 mM 
NEAA (MEM-DA).   
 
    For dose-dependent expression, hepatocytes were infected with Ad-ACSL1 at 
multiplicities of infection (MOIs) of 5, 10, 20 or 50 for 2 h.  Uninfected cells or Ad-GFP 
infected cells (20 MOI) served as controls.  After 18 h, cells were washed with cold PBS 
and homogenates were collected as described below.  For the time-course, hepatocytes were 
infected with Ad-GFP or Ad-ACSL1 at an MOI of 20. Homogenates were collected after 12, 
18, 24, 26, or 36 h of incubation for Ad-ACSL1 infected cells and after 18 h of incubation for 
Ad-GFP infected cells.   
 
Cell labeling and lipid extraction and analysis.  Twenty-one h after adenoviral infection 
(Ad-GFP or Ad-ACSL1) at 20 MOI, hepatocytes were labeled with MEM containing 1.0 µCi 
of [1-14C]oleate bound to FA-free BSA in a 3:1 molar ratio for 3 h (22).  The radiolabeling 
medium, which included 1 mM carnitine, contained a final concentration of 100 µM or 750 
µM oleate (132).  In some experiments cells were incubated with 250 µM 
[1,2,3-3H]glycerol (1.1 µCi) or 2.5 mM [1-14C]acetate (1.0 µCi).  The medium was 
collected for acid-soluble metabolites (ASM) measurement or extracted to measure 
radiolabel incorporation into secreted lipids (22,132).  Hepatocytes were washed twice with 
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1% BSA in PBS at 37oC and cellular lipids were extracted (116).  For pulse-chase 
experiments, hepatocytes were infected with adenovirus for 21 h (as above) and incubated 
with 750 µM [1-14C]oleate in the presence of 250 µM unlabeled glycerol, or with 250 µM 
[1,2,3-3H]glycerol in the presence of 750 µM unlabeled oleate.  After a 3 h incubation, the 
cells were either collected (pulse) as described above, or washed twice with 1% BSA in PBS 
and then incubated for an additional 14 h in MEM-DA without added oleate or glycerol 
(chase).  The medium and cells were collected and lipids were extracted as described.   
 
    Aliquots of the lipid extracts from the cells and media were separated by thin layer 
chromatography (TLC) on 0.25-mm silica gel G plates in either hexane:ethyl ether:acetic 
acid (80:20:1; v/v) for neutral lipids (22) or in chloroform:methanol:acetic acid:water 
(50:37.5:3.5:2; v/v) for PL (133), together with authentic lipid standards in parallel.  The 
14C- or 3H-labeled lipids were detected and quantified with a Bioscan 200 Image System.  
 
Cell homogenate preparations for ACS activity and ACSL protein assays.  Hepatocytes 
infected with Ad-ACSL1 or Ad-GFP were washed twice with cold PBS and collected in cold 
Medium A (10 mM Tris pH 7.4, 250 mM sucrose, 1 mM EDTA, 1 mM dithiothreitol and 
Protease Inhibitor Cocktail [Sigma]) and homogenized on ice with 10 up-and-down strokes 
with a Teflon-glass motor-driven homogenizer.  Homogenate aliquots were stored at –80oC 
until use.  Protein concentrations were determined by the BCA method (Pierce).  ACS 
specific activity was determined by measuring the production of [14C]acyl-CoA in the 
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presence of 175 mM Tris-HCl, pH 7.4, 8 mM MgCl2, 5 mM dithiothreitol, 10 mM ATP, 0.25 
mM CoA, and 50 µM [14C]palmitic acid in 0.5 mM Triton X-100, 0.01 mM EDTA.   The 
assays were performed in a total volume of 200 µl at 37 °C for 5 min.   The reaction was 
started by adding 0.5 to 1.5 µg of homogenate protein, terminated with 1 ml Dole’s reagent 
(isopropanol, heptane, 1M H2SO4; 80:20:2; v/v), and extracted (134).  Enzyme assays 
measured initial rates.  
 
Western Blot analysis.  Homogenates from the dose-dependent infection and time-course 
incubations (10 µg) were separated by electrophoresis on a 10% polyacrylamide gel with 
0.1% SDS, and transferred to a polyvinylidene fluoride membrane (Bio-Rad).  
Immunoreactive bands were detected by incubating the membranes with anti-FLAG M2 
monoclonal antibody (Sigma), horseradish peroxidase-conjugated goat anti-mouse 
immunoglobulin G, and SuperSignal West Pico Chemiluminescent Reagent (Pierce) (135).   
 
Quantitative Real-time-PCR.  Hepatocytes were plated at 4.5 x 106cells per 100 mm dish 
and infected with Ad-GFP or Ad-ACSL1 at an MOI of 20 for 2 h as described above.  
Thirty h after infection, RNA was isolated (RNeasy, Qiagen) and stored at -80oC until use.  
Samples were analyzed on an ABI Prism 7700 sequence detection system (Applied 
Biosystems).  Primers and corresponding FAM probes are listed in Table 3.1 except for 
CPT1 (Applied Biosystems, Rn00580702_m1).  Data were analyzed using the relative 
standard curve method (22). 
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Immunocytochemistry.  Primary hepatocytes (100,000 cells/well) were plated on 8-well 
chamber slides (Lab-Tek) coated with collagen I (Sigma) and infected with Ad-ACSL1 for 
18 h as described above.  After washing three times with PBS at room temperature cells 
were fixed with 4 % formaldehyde and permeabilized with 0.1% Triton-X100.  After 
blocking with 10% FBS in PBS cells were labeled with anti-FLAG M2 monoclonal antibody 
[1:400, Sigma] and individual organelle markers (anti-calnexin polyclonal antibody [1:100, 
Abcam], anti-VDAC polyclonal antibody [1:100, ABR], rhodamine phalloidin [1:100, 
Molecular Probes]) in blocking buffer for 1 h at room temperature.  Secondary labeling was 
performed with Alexa Fluor® 488 goat anti-mouse IgG (1:1000) or Alexa Fluor® 568 goat 
anti-rabbit IgG (1:1000, Molecular Probes).  Multichannel confocal microscopy was 
performed sequentially with a Zeiss 510 Meta Inverted Laser Scanning Confocal Microscope.  
LSM 510 Meta software was used for acquisition and image analysis. 
 
Statistical analysis.  Data from each group were expressed as means ± SE.  Data were 
analyzed by Student’s t-test, and significance was declared at p < 0.05. 
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RESULTS 
Adenoviral overexpression of ACSL1 increased ACS activity in rat primary hepatocytes.  
We infected rat primary hepatocytes with Ad-GFP or an adenovirus containing rat ACSL1 
with a FLAG epitope at the C terminus (Ad-ACSL1) and measured the ACS specific activity 
with palmitate at different virus doses (Figure 3.1A) and incubation times (Figure 3.1B).  
After an 18 h infection with Ad-GFP, ACS specific activity did not change (167.8 ± 4.9 vs. 
155.0 ± 2.6 nmol/min/mg protein in uninfected cells).  In contrast, Ad-ACSL1 (18 h) 
increased ACS specific activity 86% to 236% at 5 to 50 MOI, with a linear increase through 
20 MOI.  Ad-ACSL1 at 20 MOI increased ACS specific activity linearly for 36 h.  Western 
blotting with anti-FLAG primary antibody showed a band of about 75 kDa, confirming that 
the increase in ACS specific activity was due to the overexpression of ACSL1.  Consistent 
with the increase in activity, the density of the immunoreactive band increased with the time 
of incubation and the adenovirus dose.  For labeling experiments, we chose 20 MOI and 24 
h when ACS specific activity was increased 3.7-fold.  ACSL4 or ACSL5 are the two other 
major ACSLs expressed in rat liver.  Overexpressed ACSL1 increased ACSL5 mRNA 
expression 2-fold but ACSL4 mRNA expression was not altered (Table 3.2).  
 
Overexpressed ACSL1 colocalized with ER but not mitochondria or plasma membrane.  
Previous studies that used subcellular fractionation showed that endogenous ACSL1 in rat 
liver is located in ER, but not mitochondria (64,80).  To characterize the intracellular 
location of overexpressed ACSL1, we used confocal microscopy to examine its distribution.  
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Table 3.1.  Primer and probe sequences used for gene expression by qRT-PCR for rat 
primary hepatocytes. 
 
Genes Primers & Probes 
ACSL4 
Forward:  TATGGGCTGACAGAATCATG    Reverse:  CAACTCTTCCAGTAGTGTAG 
Probe:    TAACTTCAGTAACTGTTCCAGCCC 
ACSL5 
Forward:  GGCCAAACAGAATGCACAG    Reverse:  GGAGTCCCAACATGACCTG 
Probe:    TGTCCAGTCCCCAGGTGATGTAAT 
DGAT2 
Forward:  GGAACCGCAAAGGCTTTGTA   Reverse:  CTCCAAAGGAATAGGTGGGA
Probe:    AGCTGGCCCTGCGCCATGG 
ACAT2 
Forward:  TATACTGCCAGGAGTGGTAC   Reverse:  AGGTGTCACCAGCTCCCAAA 
Probe:    CTGTCCCTTGCCCCAGCCGA 
β-actin 
Forward:  TGCCTGACGGTCAGGTCA     Reverse:  CAGGAAGGAAGGCTGGAAG 
Probe:    CACTATCGGCAATGAGCGGTTCCG 
 
 
 
Table 3.2.  Comparison of liver gene expression levels between Ad-GFP and Ad-ACSL1 
infected rat primary hepatocytes. 
 
Genes Ad-GFP Ad-ACSL1 T-test 
ACSL4 0.87 ± 0.30 1.56 ± 0.30 NS 
ACSL5 0.66 ± 0.31 1.39 ± 0.66 * 
DGAT2 0.86 ± 0.20 1.23 ± 0.08 NS 
ACAT2 0.66 ± 0.20 1.02  ± 0.17 NS 
CPT1 0.54 ± 0.06 0.51 ± 0.03 NS 
Abundance of mRNA was quantified using qRT-PCR and normalized to β-actin.  Data 
represent means ± SE (n = 6).  * p < 0.05 by paired Student’s t test.  NS, non significant, p 
> 0.05. 
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Figure 3.1.  Acyl-CoA synthetase (ACS) activity increased in rat hepatocytes 
overexpressing ACSL1.  Rat primary hepatocytes (1.5 x 106 cells/60 mm dish) were 
uninfected (control) or infected with adenoviruses carrying either GFP (Ad-GFP) or rat 
ACSL1 (Ad-ACSL1).  A) Cells were infected with Ad-ACSL1 at different MOI as 
indicated.  After an 18 h incubation, cells were scraped and homogenized.  B) Cells were 
infected with Ad-GFP or Ad-ACSL1 (MOI = 20) and homogenates were collected at the 
indicated times.  Total ACS activity was measured and Western blot with anti-FLAG 
monoclonal antibody was performed as described under “Experimental procedures”.  Data 
are reported as means ± SE from triplicate dishes.  All Ad-ACSL1 versus Ad-GFP, p < 
0.001. 
 
B
AC
S 
Sp
ec
ifi
c 
Ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
75 kD —
0
200
400
600
800
1000
1200
1400
18 h 12 h 18 h 24 h 26 h 36 h
Ad-
GFP
Ad-
ACSL1
AC
S 
Sp
ec
ifi
c 
Ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
A
AC
S 
Sp
ec
ifi
c 
Ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
0
100
200
300
400
500
600
700
(MOI)
75 kD —
20 5 10 20 50
Ad-
GFP
Ad-
ACSL1control
AC
S 
Sp
ec
ifi
c 
Ac
tiv
ity
 
(n
m
ol
/m
in
/m
g 
pr
ot
ei
n)
  71
ACSL1-FLAG labeling was confined to intracellular membranes that partially colocalized 
with the ER marker calnexin (Figure 3.2A), but did not colocalize with the mitochondrial 
marker VDAC (Figure 3.2B), or sub-plasma membrane actin filaments and stress fibers 
(Figure 3.2C), indicating the absence of mitochondrial and plasma membrane association in 
primary hepatocytes.  The location of ACSL1-FLAG did not change with prior incubation 
with 750 µM oleate or 10 µM forskolin, and ACSL1-FLAG labeling was well colocalized 
with large regions of fluorescent-ConcanavalinA, an ER-Golgi stain (data not shown).  
These data define a fixed location for ACSL1-FLAG on ER membranes.  Thus, the 
subcellular location of overexpressed ACSL1-FLAG in hepatocytes was similar to that of 
endogenous ACSL1 in liver (64).   
 
Ad-ACSL1 increased [1-14C]oleate incorporation into DAG but not TAG, and decreased 
[1-14C]oleate incorporation into CE.  To determine the effects of overexpressed ACSL1 
on lipid metabolism, we incubated the adenovirus infected hepatocytes with 100 µM or 750 
µM [1-14C]oleate, representing physiological concentrations of exogenous FA under fed or 
fasting conditions, respectively.  At 100 µM oleate, incorporation of [1-14C]oleate into 
[14C]DAG doubled with Ad-ACSL1 (Figure 3.3A).  Increasing exogenous oleate to 750 µM 
resulted in a 1.7-fold increase of [14C]DAG in cells infected with Ad-GFP, and this was 
doubled again by the presence of Ad-ACSL1.  Surprisingly however, despite the 
Ad-ACSL1-mediated increase in [14C]oleate incorporation into DAG, the incorporation of 
oleate into TAG remained unchanged at both oleate concentrations (Figure 3.3B).  The  
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Figure 3.2.  Ad-ACSL1 colocalized with endoplasmic reticulum (ER).  Primary 
hepatocytes were plated on 8-well chamber slides (100,000 cells/well) and infected with 
Ad-ACSL1 at 10 MOI for 18 h.  Cells were fixed, permeabilized, and doubly labeled with 
primary antibodies against FLAG (green) and one of the organelle markers (red).  
Appropriate species Alexa-coupled secondary antibodies were used for detection.  A) 
Anti-calnexin (ER marker); B) Anti-VDAC (mitochondria marker); C) Rhodamine phalloidin 
(actin dye).  Yellow dots in merged A) indicate partial colocalization of ACSL1FLAG with 
ER.  Cells stained only with red were uninfected cells.  Cells were examined by confocal 
microscopy at 63x magnification.  Scale bar, 10 µm.  Images are from a representative 
experiment that was repeated three times. 
FLAG Calnexin Merge
FLAG VDAC Merge
FLAG Actin Merge
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Figure 3.3.  ACSL1 overexpression increased [1-14C]oleate incorporation into cellular 
DAG but not TAG.  Primary hepatocytes (1.5 x 106 cells/60 mm dish) were infected with 
Ad-GFP (open bar) or Ad-ACSL1 (filled bar) at 20 MOI.  After a 21 h infection, cells were 
incubated with 100 µM or 750 µM [1-14C]oleate for 3 h and harvested.  Cellular lipids were 
extracted and [1-14C]oleate incorporation into neutral lipid species was determined by TLC 
as described under “Experimental procedures”.  [1-14C]oleate incorporation into cellular A) 
DAG; B) TAG; C) CE; and D) unesterified fatty acid (FA).  Data are reported as means ± 
SE from a representative experiment performed in triplicate dishes that was repeated four 
times.  Ad-ACSL1 versus Ad-GFP, * p < 0.05, ** p < 0.01. 
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addition of 750 µM oleate increased [14C]TAG 5-fold in both Ad-GFP and Ad-ACSL1 
infected cells.  Cellular TAG mass also remained unchanged by the presence of excess 
ACSL1 (data not shown).  Decreasing the adenovirus dose to 10 MOI did not change the 
incorporation pattern (data not shown), thereby excluding the possibility that cell toxicity 
related to excess Ad-ACSL1 had inhibited TAG synthesis.  Further, the mRNA level of 
DGAT2, the major enzyme that converts DAG to TAG in liver (136), was unchanged in 
Ad-ACSL1 infected cells (Table 3.2).   
 
    Acyl-CoAs are also substrates for cholesterol esterification.  Compared to Ad-GFP 
control hepatocytes, the incorporation of [1-14C]oleate into CE was 70% lower in Ad-ACSL1 
cells at both 100 µM and 750 µM (Figure 3.3C), suggesting that ACSL1 channels acyl-CoAs 
away from cholesterol esterification.  An alternate interpretation, is that ACAT2, the major 
enzyme for CE synthesis in rodent liver (137) was downregulated.  This seemed less likely 
because the abundance of ACAT2 mRNA was unchanged (Table 2).  Finally, despite a likely 
increase in the rate of FA conversion to acyl-CoA, the amount of unesterified [14C]oleate 
present in the cells did not decrease (Figure 3.3D).  
 
ACSL1 overexpression increased [1-14C]oleate incorporation into specific PL.  In 
addition to its effects on neutral lipids, Ad-ACSL1 increased [1-14C]oleate incorporation into 
total cellular PL 70% and 21% with 100 µM and 750 µM oleate, respectively (Figure 3.4A).  
At 100 µM oleate, Ad-ACSL1 increased oleate incorporation into (phosphatidylethanolamine) 
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PE 164% (Figure 3.4B), phosphatidylinositol (PI) 104% (Figure 3.4C), and 
phosphatidylcholine (PC) 54% (Figure 3.4D).  At 750 µM oleate, Ad-ACSL1 
overexpression increased labeled PE 99% and labeled PI 56%, with no change in labeled PC.  
Thus, it appears that overexpression of ACSL1 enhanced oleate incorporation predominantly 
into PE and PI, phospholipids that originate from DAG and phosphatidic acid, respectively.   
 
ACSL1 overexpression did not affect the use of [1-14C]oleate for β-oxidation.  To 
determine whether overexpressed ACSL1 provided acyl-CoAs for FA oxidation, we 
measured labeled ASM in the medium as an indicator of FA β-oxidation (132).  ASM is 
considered a more accurate measure of β-oxidation than is CO2 production (138).   The 
incorporation of [1-14C]oleate into ASM was equal in Ad-ACSL1 infected cells and Ad-GFP 
control cells at both 100 µM and 750 µM oleate (Figure 3.5A), and there was no difference 
in the mRNA abundance of CPT1, the rate-limiting enzyme for β-oxidation (Table 3.2).  
Thus, overexpression of ACSL1 did not enhance FA degradation.   
 
Ad-ACSL1 decreased [14C]TAG secreted into the medium.  Despite similar 
incorporation of oleate into cellular TAG in Ad-ACSL1 and Ad-GFP infected hepatocytes, 
Ad-ACSL1 overexpression decreased the amount of labeled TAG secreted by about 53% 
(Figure 3.5B).  In contrast, the incorporation of [14C]oleate into secreted DAG and PL 
remained unchanged (data not shown).  These data suggested that ACSL1 activation of FA 
resulted in the synthesis of TAG that was not available for VLDL biogenesis.  
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Figure 3.4.  ACSL1 overexpression increased [1-14C]oleate incorporation into cellular PL.  
Hepatocytes were infected with either Ad-GFP (open bar) or ACSL1 (filled bar) for 21 h, and 
incubated with 100 µM or 750 µM [1-14C]oleate for 3 h.  Cellular lipids were extracted and 
[1-14C]oleate incorporation into different PL species was determined by TLC.  [1-14C]oleate 
incorporation into cellular A) PL; B) PE; C) PI; and D) PC.  Data are reported as means ± 
SE from a representative experiment performed in triplicate dishes that was repeated four 
times.  Ad-ACSL1 versus Ad-GFP, **p < 0.01, *** p < 0.001. 
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Figure 3.5.  ACSL1 overexpression decreased [1-14C]oleate metabolism to medium TAG 
but not to β-oxidation.  Hepatocytes were seeded and infected with Ad-GFP (open bar) or 
Ad-ACSL1 (filled bar) as described under “Experimental procedures”.  Cells were 
incubated with 100 µM or 750 µM [1-14C]oleate for 3 h and the cells and medium were 
collected and extracted.  Total FA metabolized includes cell and medium lipids and ASM.  
[1-14C]oleate incorporation into A) medium ASM; B) medium TAG; C) total [1-14C]oleic 
acid metabolized.  Data are shown as means ± SE from a representative experiment 
performed in triplicate dishes and that was repeated four times.  Ad-ACSL1 versus Ad-GFP, 
** p < 0.01, *** p < 0.001. 
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Overexpression of ACSL1 did not increase the total amount of FA metabolized.  When 
ACSL5 is overexpressed in McArdle-RH7777 rat hepatoma cells (22), or when ACSL1 is 
overexpressed in fibroblasts, the uptake of exogenous FA is enhanced (16), suggesting that 
FA metabolism facilitates the ingress of FA.  To determine whether ACSL1 similarly 
enhances FA uptake by hepatocytes, we calculated the total amount of [1-14C] incorporated 
into cell and medium lipids and into medium ASM.  Ad-ACSL1 did not significantly 
increase the total amount of FA metabolized at either 100 µM oleate (p=0.057) or 750 µM 
oleate (p=0.093) (Figure 3.5C).  Thus, in hepatocytes, unlike other cells, exogenous FA 
uptake was not enhanced by excess ACSL1 activity, perhaps because ACSL1 had a different 
subcellular location or because there were tissue-specific differences in interacting proteins 
(16,20).  
 
ACSL1 increased oleate recycling to TAG and PL during the chase.  Cellular complex 
lipids undergo dynamic changes via hydrolysis, re-modeling, and re-esterification (139,140).  
Thus, we wondered whether the absence of enhanced [14C]oleate incorporation into TAG 
despite a doubling of [14C]DAG was due to increased TAG hydrolysis or to diminished TAG 
reacylation.  To examine these possibilities, we labeled cells with 750 µM [1-14C]oleate for 
3 h and followed the fate of labeled complex lipids for 14 h afterwards.   
 
    In Ad-GFP infected hepatocytes, 33% of the labeled cellular TAG was lost during the 14 
h chase (Figure 3.6A).  Overexpression of ACSL1 attenuated the loss of label from TAG, 
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resulting in only an 18% decrease, and also helped to retain label present in PL.  In contrast, 
the amount of labeled PL decreased 19% in the Ad-GFP infected cells.  The diminished 
changes in the amount of [14C]-labeled TAG and lack of change in the amount of 
[14C]-labeled PL suggested that Ad-ACSL1 enhanced FA reesterification of TAG and PL.  
Since the amount of labeled DAG decreased 27% in Ad-GFP controls during the chase, 
whereas it decreased 59% in the cells that overexpressed ACSL1 (Figure 3.6A), it appeared 
that ACSL1 maintained label in TAG and PL partly by reesterifying FA that had been 
released from DAG. 
 
ACSL1 decreased the recycling of oleate into CE and β-oxidation metabolites.  In both 
the Ad-GFP and Ad-ACSL1 cells during the 14 h chase, the amount of [14C]-label in CE 
increased markedly compared to the label present at 3 h (Figure 3.6B).  However, 64% less 
label was recycled into CE in Ad-ACSL1 cells.  This decrease in [14C]CE was similar to the 
reduced labeling (70%) observed during the initial 3 h incubation, and was consistent with 
the interpretation that ACSL1 directs acyl-CoAs away from CE synthesis.  In contrast, 
however, to the lack of effect of Ad-ACSL1 on [14C]ASM observed during the 3 h pulse 
(Figure 5A), Ad-ACSL1 infected cells incorporated 42% less label into ASM during the 
chase.  These data suggested that the 14C-label in TAG and PL was retained at the expense 
of FA oxidation (Figure 3.6C). 
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Figure 3.6.  Overexpression of ACSL1 altered [14C]oleate recycling in hepatocytes.  
Hepatocytes were plated and infected with Ad-GFP (open bar) or Ad-ACSL1 (filled bar) for 
21 h.  Cells were labeled with 750 µM [1-14C]oleate for 3 h, and then were either collected 
for lipid extraction (pulse), or were washed and incubated with new media containing no FA 
for 14 h (chase), as described under “Experimental procedures”.  The remaining [14C]-label 
was analyzed in cellular lipid extracts or medium ASM in chased cells, and compared with 
pulsed cells.  A) Remaining label in cellular lipids as a percentage of the label present at 3 h 
pulse, label in TAG decreased from 179,114 ± 4,242 DPM to 120,231 ± 5,106 DPM/1.5 x 106 
Ad-GFP cells and from 167,514 ± 4,843 DPM to 138,119 ± 2,032 DPM/1.5 x 106 Ad-ACSL1 
cells, label in DAG decreased from 11,732 ± 588 DPM to 8,577 ± 242 DPM/1.5 x 106 
Ad-GFP cells and from 21,740 ± 488 DPM to 8,912 ± 374 /1.5 x 106 Ad-ACSL1 cells; B) 
[14C]oleate incorporation into cellular CE during the 3 h pulse and 14 h chase;  C) 
[14C]oleate incorporation into ASM during the 14 h chase.  Data are shown as means ± SE 
from a representative experiment performed in triplicate dishes and that was repeated three 
times.  # Significantly different from pulsed cells, p < 0.01; Ad-ACSL1 versus Ad-GFP, * p 
< 0.05, ** p < 0.01, *** p < 0.001. 
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Overexpressed ACSL1 increased [14C]oleate incorporation into DAG and PL via both de 
novo and reacylation pathways.  To determine whether overexpressed ACSL1 affected de 
novo glycerolipid synthesis, we incubated hepatocytes with 250 µM [1,2,3-3H]glycerol in the 
presence of 750 µM unlabeled oleate for either 3 h or for 3 h followed by a 14 h chase in the 
absence of labeled glycerol.  Similar to the pattern of oleate incorporation during a 3 h 
incubation, overexpressed ACSL1 increased [3H]glycerol incorporation into DAG and PL 
79% and 14%, respectively (Figure 3.7A), suggesting that ACSL1 increased de novo 
synthesis of DAG and PL.  Since ACSL1 overexpression increased incorporation into DAG 
and PL from oleate more than from glycerol, it is likely that reacylation contributed to the 
increase in labeled DAG and PL.  Similar to the [14C]oleate study,  [3H]TAG remained 
unchanged by Ad-ACSL1, again suggesting that ACSL1 overexpression did not increase de 
novo TAG synthesis despite the increase in [3H]DAG.  During the chase, again similar to the 
effects of ACSL1 on [14C]oleate recycling, more [3H]TAG and [3H]PL and less [3H]DAG 
remained in the Ad-ACSL1 infected cells (Figure 3.7B), confirming that ACSL1 altered lipid 
recycling in the hepatocytes by retaining labeled TAG and PL and by metabolizing DAG.   
 
ACSL1 overexpression increased the incorporation of FA derived from de novo 
synthesis into TAG, DAG and PL.  Liver metabolizes both FA imported from the blood 
and FA synthesized de novo.  It has been suggested that FA derived from different sources 
might have distinct fates (141).  We reported that ACSL5 exclusively activates exogenous 
FA but not FA synthesized endogenously (22).  To examine the selectivity of ACSL1, we 
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labeled the adenovirus infected hepatocytes with 2.5 mM [1-14C]acetate.  ACSL1 increased 
[1-14C]acetate incorporation into DAG and PL 83%, and 61%, respectively (Figure 3.7C), 
similar to the effect observed with [14C]oleate incorporation (Figure 3).  In contrast, 
however, to the [14C]oleate study, overexpressed ACSL1 enhanced [1-14C]acetate 
incorporation into TAG 13%, and did not significantly decrease [14C]acetate incorporation 
into CE.  Lack of effect on [14C]CE may reflect the fact that most of  the [14C]-label in CE 
was probably derived from de novo synthesized cholesterol rather than from FA synthesis.  
Thus, it appeared that ACSL1 can activate FA derived from both exogenous and de novo 
sources and commit them to the synthesis of DAG and PL.   
  83
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  ACSL1 overexpression increased [1,2,3-3H]glycerol incorporation into DAG 
and PL, and activates FA derived from do novo synthesis.   Primary hepatocytes (1.5 x 106 
cells/60 mm dish) were infected with Ad-GFP (open bar) or Ad-ACSL1 (filled bar) at 20 
MOI for 21 h.  Cells were labeled with 250 µM [1,2,3-3H]glycerol in the presence of 750 
µM unlabeled oleate (A, B) or 2.5 mM [1-14C]acetate (C).  Cells were either collected for 
lipid extraction after 3 h labeling (pulse) (A, C), or were washed and incubated with new 
media containing no glycerol nor FA for 14 h (chase) (B), as described under “Experimental 
procedures”.  Remaining [14C] label was analyzed in cellular lipid extracts in chased cells, 
and compared with pulsed cells.  Data are shown as means ± SE from 6 dishes.  # 
Significantly different from pulsed cells, p < 0.05; Ad-ACSL1 versus Ad-GFP, * p < 0.05, ** 
p < 0.01, *** p < 0.001.  
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DISCUSSION 
    The major findings of this study are that overexpression of ACSL1 altered FA 
incorporation into specific pathways in rat primary hepatocytes, and that these pathways 
differed from those previously observed after overexpression of ACSL1 in other types of 
cells.  Previous studies in NIH3T3 fibroblasts and PC12 neuronal cells strongly suggest that 
overexpressed ACSL1 provides acyl-CoAs that are incorporated primarily into TAG (63,128), 
and in vivo studies of ACSL1 heart-specific transgenic mice show a marked increase in heart 
TAG mass (86).  In addition, during the differentiation of 3T3-L1 preadipocytes into 
adipocytes, ACSL1 mRNA increases 160-fold whereas other ACSL isoforms remain 
unchanged, concomitant with a 100-fold increase in microsomal ACS specific activity and 
TAG accumulation (63,90).  ACSL1 mRNA is upregulated in liver by PPARα (97,99) and in 
adipose tissue by PPARγ (142), suggesting that the function of ACSL1 might differ in these 
tissues. 
  
    In contrast to other overexpression studies of ACSL1 (128) and ACSL5 (22), 
overexpressed ACSL1 in hepatocytes did not increase TAG mass or [14C]oleate incorporation 
into TAG despite a doubling in [14C]oleate incorporation into DAG.  Because less [14C]TAG 
was hydrolyzed in the Ad-ACSL1 infected cells during the 14 h chase, it appeared that 
ACSL1 overexpression either diminished the rate of lipid hydrolysis or increased recycling 
of hydrolyzed [14C]oleate back to TAG.  We favor the latter explanation because more 
[14C]DAG was lost from the Ad-ACSL1 infected cells.  Thus, an increase in glycerolipid 
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turnover cannot explain the inconsistency between the increased [14C]DAG without a 
concomitant increase in [14C]TAG.  Incubating cells with [3H]glycerol confirmed the pattern 
seen with [14C]oleate incorporation.  In addition, consistent with the pattern of oleate 
recycling during the chase, the [3H]-label increased in TAG and PL, and decreased in DAG, 
again supporting the hypothesis that ACSL1 increases FA reacylation.   
 
    In addition to the increase in [14C]DAG, overexpressing ACSL1 increased [14C]oleate 
incorporation into PL, particularly PE and PI.  Thus, it appears that, instead of being 
channeled towards TAG synthesis, acyl-CoAs were used primarily to synthesize PL.  This is 
consistent with the previous finding that choline- and ethanolamine- glycerolphospholipid 
masses increased 50% and 15%, respectively in heart-specific ACSL1 transgenic mice (86).  
Because less [14C]PL and more [14C]DAG was hydrolyzed in Ad-ACSL1 cells during the 
chase, ACSL1 may have increased FA incorporation into PL by enhancing FA recycling or by 
increasing the use of labeled DAG.  These data are strikingly different from a study of 
overexpressed ACSL5 in McArdle-RH7777 rat hepatoma cells in which no increase was 
observed in either oleate or glycerol incorporation into cellular PL despite an increase in 
incorporation into DAG (22), again suggesting that ACSL1 and ACSL5 commit FA to 
different metabolic fates. 
 
    The incorporation of [14C]oleate into CE was markedly lower in cells that overexpressed 
ACSL1, despite unchanged ACAT2 mRNA, and increasing the exogenous oleate 
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concentration to 750 µM did not change this result, suggesting that acyl-CoA was not 
limiting.  Further, even though both Ad-GFP and Ad-ACSL1 cells were able to use 
[14C]oleate hydrolyzed from labeled glycerolipids to esterify cholesterol during the chase, the 
Ad-ACSL1 cells continued to use less for CE labeling (Figure 6B).  Thus, we conclude that 
overexpressed ACSL1 diverted oleate away from cholesterol esterification.  This diversion 
by ACSL1 contrasts with studies of ACSL5 overexpression in rat hepatoma cells which did 
not decrease oleate incorporation into CE (22).   
 
    Overexpressed ACSL1 did not alter the amount of FA oxidized during the 3 h oleate 
incubation, but during the 14 h chase 42% less [14C]oleate was released from complex lipids 
for oxidization.  Thus, even though hepatic ACSL1 is a target of PPARα (95,97,99), our 
data did not indicate that ACSL1 channels FA into the pathway of β-oxidation.  Although 
PPARα agonists upregulate genes involved in FA oxidation like CPT1 (143), they also 
upregulate DGAT activity (144) and genes involved in de novo FA and TAG synthesis, 
including acetyl-CoA carboxylase and stearoyl-CoA desaturase-1 via PPARα-mediated 
increases in the amount of nuclear sterol regulatory element binding protein-1c (130).  Thus, 
PPARα regulation of ACSL1 may enhance lipogenesis as well as increase β-oxidation.   
 
    Despite unchanged [14C]oleate incorporation into cellular TAG, Ad-ACSL1 cells 
secreted less [14C]TAG into the medium, perhaps due to insufficient CE for very low-density 
lipoprotein (VLDL) synthesis.  Although the role of CE in the assembly and secretion of 
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VLDL is controversial (145,146), CE availability appears to be important because ACAT 
inhibitors reduce apoB100 secretion in primary rat hepatocytes and HepG2 cells (147) and 
overexpression of ACAT1 and ACAT2 stimulates apoB-containing lipoproteins in 
McArdle-RH7777 cells (146).  Additionally, because in rat hepatocytes cytosolic TAG is 
not incorporated en bloc into the ER for VLDL biogenesis and secretion (148,149), the 
amount of cell TAG might not correlate directly with TAG secreted in VLDL.  Finally, 
secretion might be affected by ACSL1-mediated changes in the cellular content of FA and 
acyl-CoA which are ligands for nuclear transcription factors like the PPARs (38) and 
HNF-4α (150,151). 
  
    Overexpression of several ACSL isoforms increase the uptake of exogenous FA 
(16,22,63).  Uptake probably occurs because vectorial acylation and enhanced FA 
metabolism diminish the rate of efflux of unesterified FA from the cell (152).  For example, 
in 3T3-L1 adipocytes, in addition to its location in the ER, ACSL1 is found on glucose 
transporter 4 vesicles (153) and on the plasma membrane where it interacts with FATP1 to 
enhance the uptake and metabolism of FA to TAG (20).  Most studies have measured the 
initial rate of FA import within 1-2 min, a time frame that may not represent the 
physiological uptake of FA that is driven by transporters and metabolic demand (152).  We 
measured the total FA metabolized in cell and medium lipids and in β-oxidation products 
during a period of time that takes metabolic demands into account (22,152) .  In our study, 
ACSL1 did not significantly increase the total amount of FA metabolized by hepatocytes.  
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Since FATP1 is not present in hepatocytes (154), and since we showed that hepatocyte 
ACSL1 is not present on the plasma membrane, lack of enhanced FA uptake and metabolism 
in hepatocytes may reflect the different intracellular location of  ACSL1, its interaction with 
a different FATP isoform, or its association with different downstream enzymes that use 
acyl-CoAs.   
 
    To determine the selectivity of ACSL1 for endogenous versus exogenous FA, we 
incubated hepatocytes with [14C]acetate, which is used for de novo FA synthesis.  In contrast 
to incubations with [14C]oleate, Ad-ACSL1 increased label incorporation into TAG, as well as 
DAG and PL, showing enhanced use of de novo synthesized FA for TAG synthesis.  It has 
been suggested that TAG and CE synthesis in hepatocytes requires some FA derived from de 
novo synthesis (144,155).  Our data suggest that overexpression of ACSL1 channeled 
exogenous FA into DAG and PL, but not into TAG, in part due to insufficient endogenous FA.  
However, during the 14 h chase, the required pool of endogenous FA may no longer have 
been limiting because of the hydrolysis of TAG and PL, so that overexpressed ACSL1 could 
increase [14C]oleate incorporation into TAG.  Differing from the decrease in exogenous 
oleate used for CE synthesis, ACSL1 overexpression did not diminish [14C]acetate 
incorporation into CE, suggesting that [14C]-label in CE was derived primarily from 
cholesterol rather than FA.  
 
    In summary, consistent with our hypothesis that ACSL1 channels FA towards specific 
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pathways, adenovirus-mediated overexpression of rat ACSL1 in rat primary hepatocytes 
channeled [14C]oleate towards DAG, PE, PI and PC synthesis and away from cholesterol 
esterification.  Overexpressed ACSL1 also increased the reacylation of hydrolyzed oleate to 
TAG and PL, but diminished the amount of hydrolyzed oleate used for β-oxidation.  In 
contrast to its role in adipocytes (15), fibroblasts (16) and heart muscle (86), overexpression 
of ACSL1 in hepatocytes did not increase incorporation of [14C]oleate into TAG or increase 
the total amount of FA metabolized.  It seems likely that ACSL1 channels FA differently in 
different tissues, perhaps depending on the subcellular location of ACSL1 or the presence of 
interacting proteins specific to each cell type.  In addition, overexpressed ACSL1 activated 
both exogenous FA and FA derived from de novo synthesis, but channeled the resulting 
acyl-CoA products into different pathways.  Our study suggests that ACSL1 in hepatocytes 
plays an important role in directing FA into pathways of phospholipid synthesis, and away 
from cholesterol esterification and β-oxidation.   
CHAPTER IV 
PHOSPHORYLATION REGULATION OF ACYL-COA SYNTHETASE 1 AND 5 
    Many key enzymes in lipid metabolism are under acute regulation by lipogenic and 
lipolytic hormones.  In view of the important role of ACSL in lipid metabolism, it is very 
possible that individual ACSL isoforms are under tight regulations.  Although lipogenic and 
lipolytic hormones caused the microsomal ACS activity to change rapidly in adipocytes, no 
data existed about acute regulation of individual ACSL isoforms.  We therefore initiated 
studies in primary hepatocytes and a cultured adipocyte cell line aimed at examining the 
potential acute regulation of ACSL1 and ACSL5 by phosphorylation.  Although we found 
phosphorylated forms of ACSL1 and ACSL5, the mechanism and physiological significance 
were not solved in the data from these studies.  However, the data presented in this chapter 
provide evidence that phosphorylation might be an important regulation on ACSL isoforms, 
and this regulation might be tissue and isoform specific.   
 
  91
4.1 Hormone effects on acyl-CoA synthetase 1 and 5 - phosphorylation regulation 
INTRODUCTION 
    Long-chain acyl-CoA synthetase (ACSL) catalyzes the first step of fatty acid activation 
in lipid metabolism (66).  Since the identification of the first isoform in rat (ACSL1), our 
knowledge on ACSL has been expanded, mainly on enzyme kinetics, tissue and subcellular 
locations, functions in fatty acid uptake and channeling, and changes under physiological and 
pathological conditions (21,22,51,64,65,80).  However, acute regulation of ACSL has been 
ignored.  Whether there is acute regulation of ACSL isoforms or what the role of acute 
regulation in lipid metabolism is remains unknown.   
 
    Studies of rat primary adipocytes have shown that microsomal ACS activity is increased 
rapidly by insulin and decreased by lipolytic hormones such as norepinephrine and glucagon 
(101,102).  Since the dose-response curve for inactivation of ACS by lipolytic hormones 
issimilar to the curve for stimulation of lipolysis, it is possible that acute regulation of ACS 
plays a role in the lipid mobilization of adipocytes (102).  In fact, ACSL isoforms have been 
identified in association with lipid droplets in 3T3-L1 adipocytes, where the 
adipocyte-specific protein perilipin A and stimulated HSL are located (89,156).  It is 
believed that perilipin A coats lipid droplets in adipocytes, and when unphosphorylated, 
suppresses basic lipolysis, presumably by blocking the access of lipases to the TAG core 
(157,158).   Supporting evidence includes the decreased TAG hydrolysis by ectopically 
expressed perilipin A in 3T3-L1 preadipocytes and Chinese hamster ovary fibroblasts that 
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normally lack perilipin (157,159), and increased basal lipolysis in perilipin A knockout mice 
(160).  During hormone-stimulated lipolysis, activated PKA phosphorylates both perilipin A 
and HSL, and the phosphorylated perilipin A induces the translocation of HSL from the 
cytosol to the lipid droplets, a critical step in the stimulated lipolysis (156,161).  Mutating 
the PKA sites in both perilipin A and HSL eliminates HSL translocation to the lipid droplet 
upon PKA activation (159,162).  Thus PKA mediated phosphorylation of both perilipin A 
and HSL is critical for stimulated lipolysis in adipocytes (163). 
 
    Phosphorylation is one of the most important and abundant reversible post-translational 
modifications.  More than 30% of proteins are modified by the covalent attachment of 
phosphate, which is critical to protein function and activity (164).  Since in adipocyte 
microsomes, ACSL1 is the major ACSL isoform, we hypothesized that ACSL1 in adipocytes 
is acutely regulated by phosphorylation and dephosphorylation.  The rationale for this 
hypothesis is based on rapid changes of microsomal ACS activity in rat adipocytes by insulin, 
norepinephrine and glucagon (101,102).  In adipocytes, insulin, norepinephrine and 
glucagon decrease and increase cellular cAMP levels, respectively, thus inhibiting or 
activating PKA.  In fact, two potential phosphoryaltion sites for PKA (Ser 74 and Ser 411) 
have been predicted on ACSL1 (Scheme 1.4).  Moreover, using a peptide antibody raised 
against ACSL1 on a Western blot, we observed a 2nd band above the major ACSL1 band in 
3T3-L1 adipocytes (data not shown).    
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    In liver, ACSL5 is present in mitochondria (64), where mitochondrial GPAT1 (mtGPAT1) 
for TAG synthesis (132,165) and CPT1 for fatty acid β-oxidation are located (4).  It has 
been proposed that CPT1 and mtGPAT1 compete for acyl-CoA substrates for these opposing 
pathways (4).  Supporting this notion, a 13-fold increase in GPAT activity by 
overexpression of mtGPAT1 decreases β-oxidation products ~ 60% in hepatocytes from fed 
rats, but increases TAG synthesis 2.4-fold (132).  Moreover, the competition between CPT1 
and mtGPAT1 is under reciprocal regulation by AMP-activated protein kinase (AMPK) (166).  
AMPK phosphorylates and inactivates mtGPAT1, thus reducing TAG synthesis (166).  
Conversely, AMPK phosphorylates and inactivates acetyl-CoA carboxylase, which results in 
the decrease of malonyl-CoA and the release of its inhibition of CPT1, thus increasing fatty 
acid β-oxidation (4,166).  Since ACSL5 provides acyl-CoA for TAG synthesis (22), it may 
play a role in this competition between mtGPAT1 and CPT1 by channeling acyl-CoA to 
mtGPAT1.  Because both CPT1 (167) and mtGPAT1 are regulated by phosphorylation, we 
wondered whether ACSL5 was also under acute regulation by phosphorylation.   
 
    This study is the first one that has reported phosphorylation of any ACSL isoforms.  
We found that in rat primary hepatocytes ACSL5 was phosphorylated on threonine 192, a 
non-classical phosphorylation site.  Using an anti-phosphoserine antibody we also detected 
phosphorylated ACSL1 in 3T3-L1 adipocytes.  However, we were not able to find any 
activity change of physiological significance.  These data support our hypothesis that ACSL 
is under phosphorylation regulation.  Further studies are needed to investigate the 
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mechanism of phosphorylation of ACSL isoforms and the significance of this acute 
regulation in lipid metabolism.     
 
METHODS 
Materials.  Minimal essential medium (MEM), Dulbecco's modified Eagle's medium 
(DMEM), nonessential amino acids (NEAA), fetal bovine serum (FBS) were from 
GIBCO-BRL Life Technologies.  Rat-tail collagen I was from Collaborative Biomedical 
Products.  Dexamethasone and hormones were purchased from Sigma.   Proteinase 
inhibitor cocktail and phosphatase cocktail I and II were from Sigma.  Anti-FLAG M2 
agarose beads and antibody were from Sigma.  Anti-phosphoserine antibody was from 
Abcam.   Tris-HCl pre-cast 10% gel was from Bio-Rad (161-1458).  Triacsin C was from 
Biomol.   
 
Cell culture and adenovirus infection.  Animal protocols were approved by the UNC 
Institutional Animal Care and Use Committee.  Rat primary hepatocytes were isolated and 
cultured as described previously in Chapter III.  Cells (4.5 x 106 cell/ 100mm plate) were 
infected with recombinant adenoviruses carrying either GFP (Ad-GFP) or rat ACSL5 
(Ad-ACSL5, with a C-terminal FLAG tag) at MOI 10 (22).  Media were changed after 2 h 
and cells were incubated for 22 h before hormone treatment.    
 
    3T3-L1 cells that express a modified coxsackie and adenovirus receptor (CAR∆1) were 
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a generous gift from Dr. David J. Orlicky from the University of Colorado (168).   3T3-L1 
CAR∆1 preadipocytes were grown in DMEM + 10% FBS to 60% ~ 70% confluent and then 
infected by Ad-ACSL1 (MOI 10) for 12~14 h.  In some experiments, 3T3-L1 CAR∆1 
preadipocytes were grown to confluence and differentiated 2 days later in DMEM + 10% 
FBS supplemented with 1 µg/ml insulin, 250 nM dexamethasone, and 500 µM 
isobutylmethylxanthine (169).  Media were changed to DMEM + 10% FBS after 2 days.  
Six days after adding differentiation media, cells were infected with Ad-ACSL1 in DEME + 
2% FBS + P/S overnight at MOI 400 (after dose-despondence check on transfection 
efficiency) for 40 h.  Cells were then subject to hormone treatment. 
 
Hormone treatment and sample collection.  Adenovirus infected rat primary hepatocytes or 
3T3-L1 CAR∆1 preadipocytes were stimulated with individual hormones at such conditions 
unless otherwise indicated:  100 nM insulin x 20min, 100 nM Glucagon x 10min, 0.5 mM 
AICAR x 30min,  1 µM epinephrine x 30min, 1 mM or 2 mM 8Br-cAMP x 50 min, or 2 
mM dibutyryl-cAMP x 60 min.  For specific activity check, cells were collected in cold 
Medium I + DTT (250 mM sucrose, 10 mM Tris, pH 7.4, 1mM EDTA, 1 mM DTT) in the 
presence of proteinase inhibitor and phosphatase inhibitor cocktails.  Homogenates were 
collected on ice with 10 up-and-down strokes and aliquots were stored at -80oC.  For 
immunoprecipitation and Western blot, cells were washed with cold PBS and incubated with 
1 ml/plate cold RIPAI buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 1% Sodium deoxycholate, 0.1% SDS, supplemented with proteinase and 
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phosphatase inhibitor cocktails).  Lysates were collected after 30 min rotate on ice and 
centrifuged at 14,000 x g for 10 min at 4oC to get rid of debris.  The supernatant were 
transferred and stored at -20oC.  Protein concentrations were determined by the BCA 
method (Pierce). 
 
Immunoprecipitation & Western blot.  All steps of immunoprecipitation were conducted at 
4oC.  Lysates were diluted in RIPAI buffer (300 µg in 1 ml unless otherwise indicated) and 
incubated with anti-FLAG agarose beads (20 µl/1 ml) on a nutator overnight.  The agarose 
beads were centrifuged at 1,000 g for 5 min and the supernatant was collected to check how 
much protein was not bound in immunoprecipitation (Figure 4.3 B).  The beads were then 
washed 3 times in 1 ml cold RIPAI buffer, followed by resuspension in SDS-PAGE sample 
buffer.  Immunocomplex was eluted by boiling the beads and then subject to SDS-PAGE.  
For Western blot, proteins separated by SDS-PAGE were transferred to PVDF or 
nitrocellulose membrane, which were then incubated with either anti-FLAG M2 monoclonal 
antibody (1/4,000) in 5% milk PBST, or rabbit anti-phosphoserine polyclonal antibody 
(1/1,500) in 3% BSA TTBS.  Immunoreactive bands were detected by SuperSignal West 
Pico Chemiluminescent Reagent after the membranes were incubated with corresponding 
secondary antibodies.   
 
Preparation for mass spectrometry.  Lysates collected from Ad-GFP or Ad-ACSL5 infected, 
hormone stimulated primary hepatocytes were subject to immunoprecipitation with 
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anti-FLAG M2 agarose (300 µg protein with 20 µl beads in 1 ml RIPAI).  The eluted 
immunocomplex was loaded on 10% Tris-HCl pre-cast gel (Bio-Rad 161-1458) for 
SDS-PAGE.  The gel was then fixed in 25% isopropanol/10% acetic acid/65% Milli-Q* 
water for 25 min and stained in 0.01% BioRad R-250 Coomassie/10% acetic acid overnight 
on an orbital shaker.  Protein bands were in-gel tryptic digested and the peptides were 
extracted for mass spectrometry analysis in the UNC Proteomics Core Facility.   
 
Mouse mitochondria isolation and PPase treatment.  Liver mitochondria were isolated 
from mouse by differential centrifugation (170).  Briefly, livers were removed and minced 
in Medium I + DTT + proteinase inhibitor (250 mM sucrose, 10 mM Tris, pH 7.4, 1mM 
EDTA, 1 mM DTT), in the absence or presence of phosphatase inhibitor cocktails I and II.  
Tissue was then homogenized on ice and centrifuged at 600 x g for 5 min to remove large 
debris and nuclei.  The supernatant was centrifuged at 10,300 x g for 10 min to obtain 
mitochondrial pellet, which was then homogenized in Medium I + DTT + proteinase 
inhibitor cocktail, in the absence or presence of phosphatase inhibitor cocktails I and II, 
according to first homogenation step.  Aliquots were stored at -80oC.  
 
ACS activity assay.  ACS activity was determined in adenovirus infected and hormone 
stimulated hepatocytes or 3T3-L1 cells, and mouse liver mitochondria fractions.  The 
activity assay measured the production of labeled acyl-CoA as described in Chapter II and III.  
In some assays, ACS activity was determined in the presence of triacsin C dissolved in 
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Me2SO (2.5% of final assay reaction).  
 
RESULTS AND DISCUSSION 
Acute regulation of hormones on ACS activity in hepatocytes.  Because liver contains 
several ACSL isoforms and very-long-chain ACSs whose substrates overlap with those of 
ACSL, effects of hormones on liver ACS activity can be complicated and not representative 
of individual ACSL.  To increase the amount of ACSL5 activity, we overexpressed ACSL5 
in rat primary hepatocytes by adenovirus (Ad-ACSL5).  In a previous study with rat 
hepatoma McArdle-RH7777 cells, Ad-ACSL5 increased total ACS activity and triacsin 
C-resistant activity 2-fold and 17-fold, respectively (22).  Extending the method to the 
current study, primary hepatocytes were infected with Ad-ACSL5, and then incubated with 
insulin, glucagon and AICAR (agonist of AMPK) for 10 – 30 min.  Surprisingly, 
Ad-ACSL5 increased total ACS activity only 12.9%, probably because of the high 
endogenous ACS activity in hepatocytes.  However, ACS activity was decreased 12% by 
insulin but increased 5% by glucagon (Figure 4.1 A) (This experiment was performed only 2 
times so that conclusion cannot be firmly drawn.).  Since ACSL5 and ACSL6 are the only 
isoforms resistant to triacsin C inhibition (21,51) and ACSL6 is not present in liver (61), 
triacsin C will differentiate ACSL5 activity from other isoforms.  Triacsin C inhibited ACS 
activity to only 8 - 10% in Ad-GFP infected cells and to 9% - 11% in Ad-ACSL5 infected 
cells (Figure 4.1 B), which is assumed to be mainly ACSL5 activity.  Similarly, triacsin C 
resistant ACS activity was decreased 19% by insulin and increased 14% by glucagon,  
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Figure 4.1.  Effects of hormones on ACS activity in Ad-ACSL5 infected hepatocytes.  
Rat primary hepatocytes (4.5 x 106cell/10cm plate) were infected with Ad-GFP or 
Ad-ACSL5 (MOI 10) for 24 h.  Cells were treated with hormones (100 nM insulin x 20 min, 
100 nM glucagon x 10 min, 0.5 mM AICAR x 30 min; NT, no hormone treatment).  
Homogenates were collected in MedI + DTT (10 mM Tris pH 7.4, 250 mM sucrose, 1 mM 
EDTA, 1 mM dithiothreitol) supplemented with protease inhibitor and phosphatase inhibitor.  
ACS specific activity was measured in the absence A) and in the presence B) of triacsin C 10 
µM.  Endogenous ACS specific activity in Ad-GFP infected cells was 138 nmol/min/mg 
protein.  ACS activity was measured with 0.5, 1.0, 1.5 µg protein.  Triacsin C does not 
inhibit ACSL5 and ACSL6 (21,51) and ACSL6 is not present in liver (61), so the triacsin C 
resistant activity is assumed to be ACSL5 activity.   The experiment was repeated once.
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indicating that ACSL5 might be acutely regulated by these hormones.   
 
    If the observed ACS activity increase by glucagon and decrease by insulin were 
mediated by phosphorylation and dephosphorylation of ACSL5, respectively, protection of 
the phosphorylated state should then increase ACSL5 activity.  Because ACS5 is located in 
mitochondria (64), to answer this question, we collected mitochondria from mouse liver in 
the absence and presence of phosphatase inhibitors.  Since in addition to ACSL5,  
mitochondria contain an undescribed triacsin-sensitive ACSL (64), triacsin C at different 
concentrations was used to differentiate ACSL5 activity from triacsin C-sensitive ACSL in 
mitochondria (Figure 4.2).  At 8 µM, triacsin C inhibited mitochondrial ACS activity to 
53% - 56%, supporting the notion that at least another triacsin C-sensitive ACSL isoform 
existed in liver mitochondria.  At all tested concentrations of triacsin C, ACS activity was 5 
– 10% higher in mitochondria collected in the presence of phosphatase inhibitors compared 
to mitochondria collected in the absence of phosphatase inhibitors.  This increase was more 
obvious at 8 µM triacsin C (10%), when ACS activity was mainly comprised of ACSL5, 
suggesting that phosphorylation might increase ACSL5 activity (Figure 4.2 B).     
 
Identification of phosphorylated ACSL5.  Following the above observation, we asked the 
question whether ACSL5 was phosphorylated and if so, by what kinase(s).  A way of testing 
this would be mass spectrometry analysis of relatively pure protein, which would identify  
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Figure 4.2.  Effects of phosphatase inhibitor treatment on ACS activity in mouse liver 
mitochondria.  A) Mitochondria from mouse liver were collected in MedI + DTT (10 mM 
Tris pH 7.4, 250 mM sucrose, 1 mM EDTA, 1 mM dithiothreitol, protease inhibitor cocktail), 
in the absence or presence of phosphatase inhibitor cocktail I and II (Sigma).  ACS specific 
activity was measured without triacsin C or with triacsin C at indicated concentrations.  
Endogenous mitochondrial ACS specific activity without phosphatase inhibitors or triacsin 
treatments was 116.2 nmol/min/mg.  ACS activity was measured with 0.5, 1.0, 1.5 µg 
protein.  B) Data were presented as percentage change of ACS activity by phosphatase 
inhibitors treatment at indicated triacsin C concentrations.  The experiment was repeated 
once.
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which amino acid(s) is phosphorylated and imply a potential kinase based on comparison 
with consensus sites (171).  To get relatively pure ACSL5, we first tried to 
immunoprecipitate the endogenous ACSL5 from rat primary hepatocytes using a peptide 
antibody raised against ACSL5.  This method did not work, possibly because peptide 
epitope was unexposed during the immunoprecipitation.  Then we infected hepatocytes with 
Ad-ACSL5, which carries an ACSL5 cDNA with a C-terminal FLAG tag, and 
immunoprecipitated ACSL5FLAG using an anti-FLAG agarose.  We were able to 
immunoprecipitate the overexpressed ACSL5FLAG (Figure 4.3 A).  Western blotting with 
anti-FLAG primary antibody confirmed the pulled down protein as ACSL5FLAG.  A 
second band of larger size was present above the major band (Figure 4.3 B).   
 
    Following immunoprecipitation and SDS-PAGE, an in gel digestion was used to extract 
peptides for MALDI-TOF mass spectrometry.  Digestion in solution could not be used 
because detergents used to increase membrane protein solubility causes significant 
difficulties in mass spectrometry (172).  The coverage of peptide extracted was 32% - 36%.  
We detected phosphorylation of threonine 192 from Ad-ACSL5 infected hepatocytes that had 
not been treated or that had been treated with AICAR.  No phosphorylated ACSL5 was 
found in hepatocytes that had been treated with epinephrine.  These data suggest that 
ACSL5 might be phosphorylated at threonine 192 under basal conditions, and that the 
phosphate might be removed with epinephrine, but not AICAR stimulation.  Sequence  
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Figure 4.3. Immunoprecipitation of ACSL5FLAG.  A) Ad-GFP or Ad-ACSL5 infected rat primary 
hepatocytes were treated with AICAR or epinephrine and collected in RIPA buffer with phosphatase 
inhibitors.  Lysates were subjected to immunoprecipitation with anti-FLAG M2 agarose.  The pull-down 
was loaded on 10% precast gel and subject to SDS-PAGE.  Coomassie-stained protein bands at the right 
size (arrows) were excised from the gel and subjected to tryptic digestion.  The tryptic peptides were 
extracted and analyzed by Mass Spectrometry in the UNC Proteomics Core Facility.  B) Lysates from 
Ad-ACSL5 infected hepatocytes (30, 50, 150 µg) were subject to Western blot directly, or after 
immunoprecipitation.  Anti-FLAG primary antibody confirmed ACSL5FLAG at right size and detected a 
2nd band.  WB: western blot directly; S: supernatant from immunoprecipitation; IP: pull-down from 
immunoprecipitation.  C) Ad-ACSL5 infected hepatocytes were treated with hormones (insulin, 100nM x 
20 min, 1 µM epinephrine x 30min, AICAR 0.5 mM x 30 min, glucagons 100 nM x 10 min).  Lysates 
were collected for immunoprecipitation by anti-FLAG agarose, followed by Western blot with 
anti-phosphoserine antibody, which was then reprobed with anti-FLAG antibody.  Ad-GFP infected 
hepatocytes served as control. 
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comparison of this site in ACSL5 from human, rat and mouse (ClustalW alignment 
http://www.ebi.ac.uk/clustalw/) showed that this threonine was located in a highly conserved 
region (Scheme 4.1) different from the ATP/AMP or the FACS signature motifs (Scheme 
1.2).  In this region, threonine 192 was one of the few amino acids that were conserved in 
rodent ACSL5, but not in human ACSL5.  Sequence alignment also showed that among the 
subfamily of rat ACSL1, ACSL5 and two variants of ACSL6, threonine 192 only existed in 
ACSL5.  Thus, it is likely that phosphorylation on this threonine is conserved in rodents, 
and is isoform specific.  This could be a mechanism by which rodent ACSL5 and its 
associated pathways are specifically regulated.  
 
    To our surprise, however, this threonine site is not predicted by the Netphos program 
(http://www.cbs.dtu.dk/services/NetPhos/) as a consensus site for any common protein kinase, 
such as PKA, protein kinase C (PKC), or AMPK.  It might be a site of casein kinase-II 
(TXXXE compared to the consensus sequence of [S/T]-(X)2-[D/E]) (Nicesite View 
http://ca.expasy.org/cgi-bin/nicesite.pl?PS00006).  However, because the function of casein 
kinase-II is unclear, and phosphorylation on threonine 192 was found in the cells before and 
after exposure to AICAR, but not to epinephrine, our data did not suggest any physiological 
significance of this phosphorylation.  Minimotif Miner (MnM) analysis 
(http://sms.engr.uconn.edu/servlet/SMSSearchServlet) showed that the region containing 
threonine 192 could be a FHA (forkhead associated protein) binding motif, which requires 
phosphorylation of threonine 192, suggesting that ACSL5 might be bound by some signal 
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Scheme 4.1.   Identification of threonine phosphorylation on rat ACSL5.  
Immunoprecipitated ACSL5FLAG bands from Figure 4.3A (arrows) were sent for mass 
spectrometry.  MALDI-TOF identified that bands as rat ACSL5 and detected 
phosphorylation on threonine 192 from cells that had not been treated or that had been 
treated with AICAR.  Sequence comparison (ClustalW, http://www.ebi.ac.uk/clustalw/) 
showed that threonine 192 was conserved in rodent ACSL5, but not in human ACSL5. 
Among the subfamily of rat ACSL1, 5, and 6, threonine 192 was only present in rat ACSL5.  
Highlighted T is the threonine 192 found to be phosphorylated in rat ACSL5. 
 
Rat ACSL5 (683aa)
Mouse ACSL5 (683aa)
Human ACSL5 (683aa)
ATP/AMP motif FACS motif
258
Putative AMP binding domain (258 – 277) (440 – 448)
Putative FA binding domain (518 – 542)
Identified phosphorylation site:  Threonine 192
277 440 448 518 542 683 aa
T192
1
Rat ACSL5
VICDTPQKALV LI GNVEK
VICDTPQKATMLI ENVEK
VICDTPQKATMLVENVEK
VIVDKPHKAI LLLEHVER
IFADKPEKAKLLLEGVEN
VICDTPQKATMLIENVEK Rat ACSL5 (683aa)
Rat ACSL1 (699aa)
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proteins and involved in signaling (173). 
 
    Since the in gel digestion extracted only 32% - 36% of the protein and did not include 
the potential PKA site or AMPK sites on ACSL5, it is possible that phosphorylation on other 
sites might have been missed.  In order to test whether ACSL5 was phosphorylated at serine 
residues, we performed immunoprecipitation followed by immunoblot with 
anti-phosphoserine (anti-PS) antibody.  Western blot with anti-PS detected serine 
phosphorylated ACSL5FLAG (Figure 4.3 C).  However, it seems that hormone treatment 
did not change the phosphorylation state, suggesting that this serine phosphorylation might 
be constitutive.  An limitation of this study is that sample without hormone treatment is 
lacking.  
 
Potential acute regulation of ACSL1 in 3T3-L1 cells?  Our finding of phosphorylated 
ACSL5 prompted us to examine whether ACSL1 was also phosphorylated, since previous 
studies from other groups showed that microsomal ACS activity was regulated rapidly by 
hormones in adipocytes, where ACSL1 was the predominant ACSL isoform.  3T3-L1 
CAR∆1 preadipocytes were used because of their very low endogenous ACS activity and 
lack of expression of ACSL1 (48,60).  These cells are infected with adenovirus at higher 
efficiency because they express modified coxsackie and adenovirus receptor (CAR) 
(168,169).  We overexpressed rat ACSL1 by recombinant adenovirus (Chapter III & 
Appendix) and checked ACS activity after different hormone treatment for 10 – 30 min.  In 
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these cells, ACS activity was increased by insulin slightly but not changed by glucagon 
(Figure 4.4 A).  Conversely, 8-Br-cAMP, a permeable analog of cAMP, decreased ACS 
activity (Figure 4.4 B).     
 
    ACSL1 has been identified in lipid droplet fractions in 3T3-L1 adipocytes.  When lipid 
droplets were isolated from 3T3-L1 adipocytes by a fractionation technique, proteomic 
analysis of lipid droplet associated proteins by mass spectrometry identified ACSL1 (89).  
Since some contaminant proteins such as fatty acid translocase (CD36) from plasma 
membrane, and ATP synthase from mitochondria, were also identified in the lipid droplet 
fractions, the validity of the ACSL1 localization needs to be further proved.  The role of 
ACSL1 in lipid droplets is unknown.  Based on previous studies and current study, we 
hypothesized that lipolytic hormones might inhibit ACSL1 activity by phosphorylation and 
that lipogenic hormones might stimulate ACSL1 activity by dephosphorylation (Scheme 4.2).  
In this proposed model, when lipid is mobilized, lipolytic hormones, such as glucagon and 
epinephrine, phosphorylate ACSL1 and HSL, which results in inhibition of ACSL1 but 
stimulation of HSL.  PKA also phosphorylates perilipin A, which facilitates the association 
of HSL to lipid droplets and hydrolysis.  Inhibition of ACSL1 while HSL is active would 
prevent the re-activation of released fatty acids and their re-esterification back to 
glycerolipids, hence preventing a futile cycle and energy waste (2 ATP/fatty acid activation).  
Conversely, during lipogenesis, lipogenic hormones might cause dephosphorylation of 
ACSL1, HSL and perilipin A, and activate ACSL1 while inhibiting HSL, thus providing  
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Figure 4.4.  Effects of hormones on ACS activity in 3T3-L1 preadipocytes infected with 
Ad-ACSL1.  A) 3T3-L1 ∆CAR preadipocytes (60%~70% confluent) were infected by 
Ad-ACSL1 (MOI 10) for 14 h.  Cells were treated with hormones (1 µM Insulin x 30 min 
or 1 µM glucagons x 30min).  B) 3T3-L1 ∆CAR preadipocytes (60%~70% confluent) were 
infected by Ad-ACSL1 (MOI 10) for 12 h and then stimulated by 8Br-cAMP (Sigma B 7880) 
at 1mM or 2mM for 50 min.  Homogenates were collected in MedI + DTT (10 mM Tris pH 
7.4, 250 mM sucrose, 1 mM EDTA, and 1 mM dithiothreitol) supplemented with protease 
inhibitor and phosphatase inhibitor, and ACS specific activity was measured.  ACS activity 
was measured with 0.5, 1.0, 1.5 µg protein.  The experiment was repeated twice.
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Scheme 4.2.  Proposed model of hormonal acute regulation of ACSL1 in adipocytes.  A) 
During lipid mobilization, lipolytic hormones (glucagon, epinephrine) bind to GPCR and 
activate AC, which produces cAMP and release the catalytic subunits of PKA.  Activated 
PKA phosphorylates perilipin A, ACSL1 and HSL, which results in inhibition of ACSL1, but 
stimulation of HSL.  Phosphorylated perilipin A facilitates the translocation of HSL from 
the cytoplasm to the lipid droplet, where efficient TAG hydrolysis occurs (161).  ACSL1 
might be located on lipid droplets (89).  Active HSL releases free fatty acids from TAG and 
inactive ACSL1 prevents fatty acid re-esterification, thus facilitating the release of fatty acids 
to plasma.  The inhibition of ACSL1 while HSL is active would prevent a futile cycle of 
TAG hydrolysis and fatty acid re-esterification.  B) During lipogenesis, lipogenic hormones 
(insulin) activate phosphodiesterase and phosphatase.  Phosphodiesterases hydrolyze cAMP 
and prevent the release of PKA catalytic subunits.  Phosphatases dephosphorylate ACSL1 
and HSL, resulting in activation and inactivation, respectively.  Active ACSL1 provides 
acyl-CoA substrates for TAG synthesis, which will be stored in lipid droplets.  AC, 
adenylate cyclase; ACSL1, long chain acyl-CoA synthetase 1; C, PKA catalytic subunit; Des, 
phosphodiesterase; FFA, free fatty acids; Gs, stimulatory G protein; GPCR, G 
protein-coupled receptor, HSL, hormone sensitive lipase; Peri A, perilipin A; PKA, protein 
kinase A; R, PKA regulatory subunit.  
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acyl-CoA substrates for TAG synthesis.  Unphosphorylated perilipin serves as a blocker 
against HSL and thus inhibit hydrolysis.  It has been reported that lipid futile cycles exist in 
adipocytes (174) but the role of ACSL1 has not been studied.  Our model thus also provides 
a potential role of ACSL1 in regulation of futile cycle and fatty acid release under different 
nutritional status.    
 
    To test this hypothesis, we tried several methods.  Our data were disappointing because 
the results showed no difference or were inconsistent.  First, rat ACSL1FLAG was purified 
by affinity chromatography method as described (Appendix 6.2), and incubated with PKA at 
different doses, immediately followed by ACS enzyme assays.  Our data did not show a 
consistent ACS activity change by PKA, nor were apparent 2nd bands found by Western blot 
with anti-FLAG antibody (data not shown).  Second, to examine whether hormone 
treatment affected ACS activity in 3T3-L1 adipocytes, we treated differentiated 3T3-L1 
adipocytes with insulin, dibutyryl-cAMP, AICAR, DiC8 (a cell permeable PKC activator), 
and isoproterenol.  We did not find a reliable change in ACS activity as previously reported 
with rat primary adipocytes.  One possibility could be that different regulation and kinase 
responses exist between 3T3-L1 adipocytes and primary adipocytes.  Third, we 
immunoprecipitated ACSL1FLAG from Ad-ACSL1 infected 3T3-L1 CAR∆1 adipocytes, 
followed by Western blot with anti-PS antibody.  Although serine phosphorylated ACSL1 
was detected, no difference in protein amount or size was found in adipocytes treated with 
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lipogenic or lipolytic hormones (Figure 4.5).    
 
Insight for future research.  The data presented in this chapter show that ACSL can be 
phosphorylated.  This post-translational modification might be isoform specific since the 
phosphorylation site identified on ACSL5 is not conserved on other ACSL isoforms.  It is 
likely that hormones elicit tissue-specific effects on different ACSL isoforms, depending on 
the physiological roles of the tissues and ACSL isoforms.  Although we did not detect 
marked changes on ACS activity by hormone treatments, regulation systems in 3T3-L1 
adipocytes might differ from those in primary adipocytes.  It is also possible that, 
phosphorylation might cause other effects, such as subcellular translocation or a 
conformational change of the ACSL isoform that alters their interaction with other proteins.   
 
    Based on the data observed, future research might exploit other methods or models to 
study the significance of acute regulation by phosphorylation.  First, sample preparation for 
mass spectrometry needs to be optimized, probably by in solution digestion, with digestible 
detergents that can be removed from membrane proteins before mass spectrometry (172).  
Second, site-directed mutagenesis can be used to change potential phosphorylation sites, 
followed by examination of enzyme kinetics.  For example, the potential serine 
phosphorylation sites for PKA in ACSL1 can be replaced with alanine (S74A and S411A) to 
block phosphorylation, or with glutamate (S74E and S411E) to mimic constitutive 
phosphorylation.  Third, site-specific antibodies can be made against phosphorylated ACSL.  
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Figure 4.5.  Phosphorylated ACSL1 in adipocytes.  Ad-ACSL1 infected 3T3-L1∆CAR 
adipocytes were treated with hormones (0.5 mM AICAR x 30 min, 2 mM dibutyryl-cAMP x 
60 min, or 40 nM Insulin x 20 min).  Lysates were collected for immunoprecipitation by 
anti-FLAG agarose, followed by Western blot with anti-phosphoserine antibody, which was 
then reprobed with anti-FLAG antibody.  Reprobing with anti-FLAG confirmed that 
detected phosphoserine bands were ACSL1FLAG.   
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Then the effects of different hormones can be studied specifically rather than with the general 
phosphoserine antibody.  Moreover, primary adipocytes model is worthy to consider 
although they need high dose of adenovirus for efficient infection. 
 
 
 
 
   
CHAPTER V 
SYNTHESIS 
    This dissertation describes three independent projects that examined the function and 
regulation of rat ACSL isoforms.  The results provide strong evidence supporting our 
hypothesis that individual ACSL isoforms provide fatty acyl-CoAs to specific downstream 
metabolic pathways.  We also showed, for the first time, that ACSL isoforms could be 
phosphorylated, which might be an important regulatory mechanism of fatty acid channeling 
by ACSL.  This chapter will summarize results from these projects and discuss how our 
finding may contribute to future research and clinical implication for treatment of obesity and 
diabetes. 
 
5.1 Different capacities of rat ACSL isoforms in replacing bacterial ACSL   
    Using a bacteria strain with its own ACSL mutated (fadD), we transformed individual 
rat ACSL isoforms to examine whether they are different in their capacities in replacing this 
sole ACSL in bacteria.  We demonstrated that only ACSL5 was able to support growth in 
the medium with oleate as the sole energy and carbon source, although the in vitro specific 
activities of all isoforms were greater than that of the endogenous FadD.  ACSL isoforms 
variably and partially restored the capacities of exogenous fatty acids transport, β-oxidation, 
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and PL synthesis.  This study added to the evidence that ACSL isoforms are not redundant, 
but functionally different.  Consistent with our finding, rat ACSL isoforms also differ in 
their capacities in replacing the ACSL in yeast (faa1∆faa4∆) (6).  In the yeast model, rat 
ACSL1, 4, and 6, but not ACSL5 rescue fatty acid transport activity and TAG synthesis.  
The different complementation between the prokaryotic and eukaryotic model systems 
suggests that membrane composition and protein-protein interactions may be critical for 
function of ACSL.  The bacterial inner membrane composition is more similar to the 
mitochondrial membrane in mammalian cells where ACSL5 is located (64), whereas the 
yeast plasma membrane is more similar to mammalian plasma membranes, where ACSL1 is 
located (6,64).   
 
    An interesting question derived from the observation in E. coli study is the importance 
of membrane location for function of ACSL.  Different organelles adopt distinct membrane 
characteristics.  For example, the mitochondria membrane contains cardiolipin (175) and 
plasma membrane contains different PL on the outer and inner leaflets (176).  Since all 
ACSL isoforms, except ACSL4, which is a peripheral membrane protein, are predicted to 
have at least one transmembrane domain (ExPASy topology prediction, 
http://www.expasy.org/tools/#topology), the subcellular location is important for their 
function.  We do not know how ACSL isoforms are targeted to distinct membranes, and 
whether their re-localization would affect their functions.  Future studies to explore this 
question would require sequence truncated ACSL and ACSL with synthetic peptide signals 
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that relocate to specific organelles.   
 
5.2 Fatty acid channeling by ACSL isoforms 
    Our study replacing E. coli FadD with rat ACSL isoforms also indicated different roles 
among them.  Thus, the next step was to examine the function of an individual isoform.  
We found that overexpression of ACSL1 in rat primary hepatocytes channeled fatty acids 
towards DAG and PL synthesis, and away from CE synthesis and medium TAG.  ACSL1 
overexpression did not change oleate incorporation into TAG or β-oxidation.  These results 
are different from the effects of ACSL5 overexpression in rat hepatoma McArdle-RH7777 
cells in a previous study from our lab (22).  Overexpression of ACSL5 increases fatty acid 
incorporation into DAG and TAG, but does not affect fatty acid used for β-oxidation, PL, CE, 
or medium TAG.  These two studies together provide direct evidence for our hypothesis that 
different ACSL isoforms have distinct functions in lipid metabolism. 
 
    We found that ACSL1 overexpression did not increase TAG synthesis in primary 
hepatocytes, unlike what occurs in heart-specific ACSL1 transgenic mice (86).  This leads 
to two interesting questions: What will be the effects of overexpression of ACSL1 in vivo?  
Does ACSL1 or/and other isoforms have tissue specific functions in lipid metabolism?  
Overexpression of ACSL1 in vivo by adenovirus infection or a transgenic technique would 
provide a more physiological model for studying the role of ACSL1 in lipid metabolism, and 
also address questions about VLDL secretion, hepatic insulin sensitivity, and response to 
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nutritional status change.  Since adenovirus mainly targets liver, to answer the second 
question of tissue-specific function, more practical methods would be in vitro studies using 
different cell types.  
 
    The pressing question arising from what we found is, what are the mechanisms behind 
the fatty acid channeling by ACSL isoforms?  The different results from replacement studies 
in E. coli and yeast, and overexpression studies of ACSL1 and ACSL5, suggest that 
protein-protein interactions might play a role in fatty acid channeling into different 
downstream pathways.  Although it has been reported that a physical association between 
ACSL and fatty acid transport proteins, such as Faa1p with Fat1p in yeast (8) and ACSL1 
with FATP1 in adipocytes (20), is important for fatty acid uptake, no study has shown 
interaction between individual ACSLs with intracellular proteins.  Our preliminary studies 
found that a protein of bigger size co-immunoprecipitated with ACSL1 (data not shown).  
Moreover, mass spectrometry analysis of protein bands that co-immunoprecipitated with 
overexpressed ACSL5 in hepatocytes identified proteins such as pyruvate carboxylase.  We 
believe that ACSL is involved in protein complexes within subcellular locations, and 
interaction between different isoforms with downstream enzymes might facilitate fatty acid 
partitioning.  Interaction of ACSL with different proteins available in specific tissues might 
mediate tissue-specific functions of ACSL.  Potential interacting proteins include fatty acid 
binding proteins that might provide substrates to ACSL, ACBP that bind acyl-CoA, which 
might release the product inhibition on ACSL, downstream acyltransferases that use 
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acyl-CoAs for different pathways, such as CPT1 for oxidation, GPAT for LPA synthesis, and 
ACAT for CE synthesis, and transcription factors that use acyl-CoAs as ligands.  To address 
this question, a yeast two-hybrid system might be used first to screen for potential interacting 
proteins at a wide scale.  Co-immunoprecipitation can then be exploited to confirm the 
interaction between ACSL1 and potential interacting proteins.  Mass spectrometry of 
proteins that are co-immunoprecipitate with ACSL1 would also be a good way to identify 
proteins that interact with ACSL1 under different conditions, such as with hormone treatment.  
However, due to the potential artificial effects (false positive interactions) when proteins are 
overexpressed (177), multiple methods should be tried to confirm an interaction.   
 
5.3 Acute regulation of ACSL isoforms   
    Acute regulation of ACSL has been relatively ignored in the literature, partly because 
ACS activity did not always respond to nutritional status (80) and because of the difficulty in 
interpreting ACSL activities which are comprised of several ACSL isoforms.  We 
hypothesized that ACSL isoforms could be regulated by phosphorylation, based on the 
reported rapid microsomal ACS activity change by hormones (insulin, epinephrine, glucagon) 
in rat adipocytes (101,102).  In addition, on a Western blot with anti-ACSL1 antibody, we 
observed a 2nd band in 3T3-L1 adipocytes (data not shown).  Since ACSL1 is predominant 
in 3T3-L1 adipocytes, and is associated with lipid droplets together with HSL and perilipin A 
(89), which are both regulated by phosphorylation, we studied potential phosphorylation on 
ACSL1 in these cells.  Moreover, we studied ACSL5 in hepatocytes because ACSL5 in liver 
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might provide acyl-CoAs for mtGPAT1, which is regulated by AMPK (166), and because 
potential AMPK sites exist in rat ACSL5.   
 
    This study is the first one to identify phosphorylated forms of ACSL.  Mass 
spectrometry following immunoprecipitation identified ACSL5 with a phosphorylated 
threonine 192, from hepatocytes that had not been treated or had been treated with AICAR.  
This threonine 192 exists only in ACSL5, but not in the other four isoforms, suggesting that 
phosphorylation could elicit isoform specific effects.  Western blot with an 
anti-phosphoserine antibody also showed phosphorylated bands after immunoprecipitation of 
ACSL5 from hepatocytes and ACSL1 from adipocytes, suggesting that ACSL5 could be 
phosphorylated at different sites.  The limit of this study, however, is that we were not able 
to solve the physiological significance of phosphorylation regulation.  Our studies with 
different hormone stimulation showed no change of either ACS activity or the density of 
phosphorylated bands.  Since multiple isoforms contribute to the total ACS activity, it is 
possible that opposite effects on individual isoforms resulted in no net change of activity.  
Alternatively, phosphorylation might elicit changes other than activity, for example, 
association of ACSL with other proteins.  Since the identified threonine 192 in ACSL5 is 
not a consensus site for common protein kinases such as PKA, PKC and AMPK, but located 
in a FHA binding motif to which proteins with an FHA domain might bind, it is possible that 
this phosphorylation is linked to signaling processes.  
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    Further study to examine the mechanism and physiological effects of phosphorylation 
would require better methods of sample preparation for mass spectrometry, since our 
extraction of peptides after in-gel digestion was only 32% - 36% and phosphorylation on 
other sites might have been missed.  After identification of phosphorylation sites, 
site-specific antibodies would detect endogenous phosphorylated proteins under different 
hormone treatment, and can be used for samples from in vivo study.  Further, site-directed 
mutagenesis can be exploited to study the importance of the phosphorylation sites.  Effects 
of phosphorylation might not be limited to activity change, although phosphorylation 
frequently affects enzyme activities.   
 
5.4 Future direction and studies 
    The most pressing and interesting questions that remain to be answered are varied.  In 
addition to studying in vivo effects of ACSL1, interaction of ACSL with other proteins, 
phosphorylation regulation, and tissue-specific functions as mentioned above, the following 
aspects would be important for us to better understand the roles of ACSL isoforms, and hence 
enable us to find potential therapeutic targets for diseases such as obesity, hepatic steatosis, 
insulin resistance, and possibly, cancer.  
 
5.4.1 ACSL1 knockout mice as a model for treatment  Since ACSL partitions fatty 
acyl-CoAs to specific downstream pathways, and the balance of anabolic and catabolic 
pathways determines the lipid accumulation in cells, the specific isoform that channels 
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acyl-CoAs to TAG synthesis will then be a potential therapeutic target for obesity and 
dyslipidemia.  ACSL1 has been shown to be associated with TAG synthesis in adipocytes 
and heart cells when overexpressed, but the potential benefits of inhibiting ACSL1 await 
studies on knockout models. 
 
    Knock out models are a powerful method to examine directly the role of ACSL in fatty 
acid channeling.  This is particularly true when multiple ACSL isoforms contribute to high 
endogenous ACS activity, which is difficult to be increased by overexpression of one isoform.  
Knock out models will then be more revealing than an overexpression approach in the tissues 
with high ACSL expression, such as liver and adipose tissues.  Following the study of 
overexpressing ACSL1 in hepatocytes, which showed differences in lipid metabolism from 
overexpressing ACSL1 in heart, we hypothesized that the role of ACSL1 might be 
tissue-specific.  That is, ACSL1 might provide acyl-CoAs for TAG synthesis in adipose 
tissue, whereas might provide acyl-CoAs for PL synthesis in liver.  Currently we are making 
liver and adipose tissue-specific ACSL1 knockout mice, which will be useful models for us 
to determine 1) whether ACSL1 is essential for lipid synthesis in adipocytes, 2) whether 
deletion of ACSL1 in liver would affect PL and CE synthesis, and VLDL assembly and 
secretion, and 3) whether an ACSL1 deletion will change the response to diet challenge or 
diet induced obesity, as well as insulin sensitivity.   
 
    If, as hypothesized, ACSL1 has tissue-specific functions, caution is needed to target 
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ACSL1 as a treatment for obesity.  Decreased PL or disturbance of PL species in liver might 
affect membrane and organelle functions, signal transduction, and assembly of VLDL, thus 
changing the morphology and function of liver cells.  
 
 5.4.2 Effects on gene expression  An interesting aspect will be to define the role of 
ACSL isoforms in affecting gene expression, because acyl-CoAs might be natural ligands for 
transcription factors (23,24,38-40).  Both ACSL protein and activity has been detected in 
nuclei of mammalian cells, and acyl-CoAs exist in nuclei fractions (41).  We found that 
LPA, which is the product of GPAT from acyl-CoA and glycerol-3-phosphate, might be a 
ligand for PPARγ (Stapleton CM and Coleman RA, unpublished).  Thus, if a specific ACSL 
isoform provides acyl-CoA to GPAT, overexpression or knockout of this isoform would elicit 
effects on gene expression by increasing or decreasing the LPA ligand for PPARγ.  Other 
potential transcriptions factors that might use acyl-CoAs are PPARα (38,39) and HNF-4α 
(40).  Both overexpression and knockout models would be useful to examine the effects of 
ACSL on the target genes of these transcription factors, and then on a broad range of 
processes including glucose and lipid homeostasis. 
 
5.4.3 ACSL in apoptosis and cancer  It has been proposed that free fatty acids and 
several lipid species initiate or promote apoptosis (1).  For example, ceramide, the product 
of saturated fatty acid, induces apoptosis (178).  Therefore, as the key enzyme for fatty acid 
activation and metabolism, ACSL may play a role in apoptosis and related diseases.  In fact, 
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ACSL isoforms have been found to change in certain tumors.  Some colon adenocarcinomas 
and colon carcinoma are associated with increases of ACSL4 or ACSL5 mRNA (70,73).  
Overexpression of ACSL4 in ECR 293 cells decreased apoptosis 25%, whereas triacsin C, 
which can inhibit ACSL4, increased apoptosis 9-fold in HT29 cancer cells (70).  It has been 
proposed that increasing the C20:4 preferring ACSL4 might decrease free C20:4, which is 
important for apoptosis (70).  Following the observation that C20:4 signals apoptosis, 
several studies have been conducted on the role of cyclooxygenase-2 in apoptosis, but the 
enzyme that transfers C20:4 to acyl-CoA, ACSL4, was ignored.  The association between 
ACSL and apoptosis is also supported by the data from ACSL1 heart transgenic mice, which 
showed increased cytochrome c release, ceramide content and apoptosis (86).  Moreover, 
we also observed decreased cell viability and changed cell morphology when primary 
hepatocytes were infected with high dose of Ad-ACSL1.  The cells became dense and round, 
formed membrane blebs, and lost their shape and contact with neighboring cells.  This did 
not occur in cells that were infected with Ad-GFP, thus excluding the possibility of toxicity 
from adenovirus infection itself. 
 
    Since ACSL isoforms are critical in fatty acid channeling, specific ACSL isoforms 
might mediate apoptosis.  For example, the mitochondrially located ACSL5 might provide 
fatty acyl-CoAs for cardiolipin remodeling which would decrease cytochrome c release and 
apoptosis.  Conversely, ACSL1 might provide acyl-CoA for ceramide synthesis, which 
would increase apoptosis.  Studies of the effects of ACSLs on apoptosis and cancer 
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development would thus provide insight into potential targets for cancer. 
 
    Taken together, the more we learn, the more questions we have.  The current studies 
further our understanding of function and regulation of ACSL isoforms, and prompt us to 
explore the mechanisms and application beyond the observations.  In the long term, we 
would be able to utilize the knowledge of specific functions of individual ACSL isoforms, 
and target individual isoforms for therapeutic aims.  
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APPENDIX I:  
DETAILED METHODS 
6.1 Construction of adenovirus carrying rat ACSL1 
    We used the method in Dr. Newgard’s lab (Duke University) to make an adenovirus 
carrying a cDNA of rat ACSL1 with a C-terminal FLAG epitope (131).  First, a full-length 
rat ACSL1 cDNA with a C-terminal FLAG epitope (DYKDDDDK) was subcloned from a 
previously constructed pTRE2hyg plasmid (pTRE2hyg-ACSL1) into a shuttle vector, 
pACCMVpLpA at the Bam HI and Sal I sites (Scheme 6.1).  The inserted ACSL1FLAG in 
resulted construct (pACCMV-ACSL1) was confirmed by restriction enzyme digestion and 
DNA sequencing at the UNC DNA sequencing facility.  Then this pACCMV-ACSL1 
plasmid was transiently transfected into CHO cells via FuGene 6 (Roche) for 24 h, with 
empty vector and the original pTRE2hyg-ACSL1 as negative and positive controls, 
respectively.  ACS enzyme assay showed increased activity (2.9-fold) by pACCMV-ACSL1 
(Figure 6.1 A) and protein size was confirmed by Western blot with anti-FLAG primary 
antibody.  Second, the shuttle vector pACCMV-ACSL1FLAG and the adenovirus vector 
pJM17 were amplified in bacteria and purified using MaxiPrep (QIAGEN).  The plasmids 
were co-transfected into 293 cells by calcium phosphate co-precipitation.  When a 
homologous recombination event occurs, the resulting recombinant adenovirus caused cell 
lysis and the formation of plaques of dead cells (Scheme 6.2).   Seven single plaques were 
picked and 293 cells were infected.  Lysates were collected and used to infect COS-7 cells, 
using uninfected cells and empty vector infected cells as controls.  The ACS enzyme assay 
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showed 49% - 89% activity increase from lysates # 1, 3, 5, 6 and 7, with #3 the highest 
increase (89%) (Figure 6.1 B).  Third, lysates #3 was sent to the UNC Vector Core Facility 
for further purification and amplification.  3T3-L1 preadipocytes were infected with 
purified adenovirus carrying ACSLFLAG (Ad-ACSL1) (1.3 x 108 pfu/µl).  At MOIs 5, 10, 
20, 50, and 100, Ad-ACSL1 increased ACS activity 3-, 10-, 19-, 40-, and 60-fold, 
respectively, showing a linear increase with dose-dependence.  Complete inhibition by 
triacsin C indicates that the increased ACS activity is due to the overexpressed ACSL1 
(Figure 6.1 C).   
 
6.2 Different substrate preferences among rat ACSL isoforms 
    When we constructed recombinant pFLAG-CTC-ACSL plasmids for E. coli FadD 
complementation study (Chapter 2.1), we identified a novel splice variant of ACSL6, which 
arises from alternative slicing of exon 13 instead of exon 14.  The newly identified 
rnACSL6_V2 cDNA has been deposited in the GenBank database (accession number 
AY625254).  This variant encodes an ACSL6 protein with 12 different amino acids (termed 
ACSL6_v2, previously reported termed ACSL6_v1).  Our previous studies purified rat 
ACSL1, 4 and 5, the three main isoforms in liver, and found distinct difference in enzyme 
kinetics.  Since ACSL3 and ACSL6 predominate in brain and their substrate preferences 
might be important for neuronal lipid metabolism and brain development, the current study 
was to directly examine the preference of these ACSL isoforms for several fatty acids 
important in brain metabolism.  Data described in this chapter was part of the work 
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published as a co-author (51). 
 
Expression of recombinant ACSL3-, ACSL4-, ACSL6_v1-, and ACSL6_v2-FLAG proteins 
in E. coli.  Recombinant plasmids for the expression of ACSL3, ACSL4 and ACSL6 with a 
C-terminal FLAG epitope were constructed (Chapter 2.1) and expressed in E. coli 
BL21-CondonPlus(DE3)-RIL which was grown at 25 oC with shaking at 250 rpm in LB 
broth supplemented with 50 µg/mL carbenicillin.  When the bacteria were in mid-log 
growth (A600 = 1.0), production of recombinant ACSL-Flag proteins was induced with 1 mM 
IPTG.  After a 15-h induction, cells were harvested by centrifuging at 5000 rpm for 10 min 
in a Sorvall HS-4 rotor.  The cell pellet was resuspended in 10 mM HEPES (pH 7.8), 0.5 
mM EDTA, and 100 µg/mL lysozyme, and incubated for 30 min on ice.  The cells were 
then sonicated with six 10-s bursts with a 10-s rest period between each burst. Sonicated 
samples were centrifuged at 5000 rpm for 10 min at 4 oC.  The supernatant was layered over 
a 2 mL cushion of 55% (w/w) sucrose topped with 0.5 mL of 5% (w/w) sucrose in 
HEPES/EDTA buffer.  After centrifugation in a SW41 rotor at 35000 rpm for 3 h at 4 oC, 
the membrane fraction was removed with a 19-gauge needle and syringe.   
 
Purification of recombinant ACSL3-, ACSL4-, ACSL6_v1-, and ACSL6_v2-FLAG 
proteins.  ACSL3-, ACSL4-, ACSL6_v1-, and ACSL6_v2-FLAG were purified by Flag M2 
column chromatography. The anti-Flag M2 antibody affinity matrix (1 mL) was activated 
with 0.1 M glycine (pH 3.5) followed by equilibration with 50 mM Tris (pH 7.4), 150 mM 
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NaCl (TBS) buffer. BL21 membrane fractions containing recombinant ACSL3-, ACSL4-, 
ACSL6_v1-, and ACSL6_v2-FLAG were solubilized in TBS containing 1% Triton X-100 
and passed over the affinity column four times.  The column was washed twice with 10 mL 
of TBS (pH 7.4), and then eluted with five 1 mL aliquots of 100 µg/mL Flag peptide 
dissolved in TBS buffer.  Lysates, cell extracts, membranes and elutes were electrophoresed 
on a 10% acrylamide gel containing 0.1% SDS and stained with Gel Code blue stain reagent 
(Pierce) (Figure 6.2).    
 
Competition ACSL Assays.  A competition ACS assay was conducted with 50 µM 
[14C]palmitate as described in Chapter 2.1, in the absence or presence of unlabeled C20:4, 
C20:5, C22:6, C18:2, or C18:3 at varying concentrations (0.5 µM – 100 µM).  The 
unlabeled fatty acids competed with labeled palmitate as substrates for ACSL isoforms.  
Thus, by measuring the labeled palmitoyl-CoA, we were able to directly examine the 
preferences of ACSL for different fatty acids.  The assay was initiated with 0.2 µg of 
purified protein and ACS activity was measured at 37 oC after a 5-min incubation (Figure 
6.3).  When assayed in the presence of increasing concentrations of unlabeled C20:4, 
ACSL4 activity was strongly inhibited with an IC50 of 0.5 µM C20:4 (Figure 6.3 C).  In 
contrast, ACSL6_v1 and ACSL3 did not have a preference for C20:4 compared with C16:1 
(IC50 ~45 µM), whereas ACSL6_v2 preferred C16:1 slightly more than C20:4 (IC50 = 90 
µM).  Indeed, ACSL4 strongly preferred all of the PUFAs tested to C16:1, with IC50 values 
ranging from 0.5 µM to 5 µM.  Since PUFAs are important precursors for eicosanoids and 
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brain phospholipids, and thus critical for brain development and function, it is possible that 
lipid metabolism change plays a role in the ACSL4 mutation-linked mental retardation (54).  
Of the isoforms tested, only ACSL4 strongly preferred C20:4 and C20:5 to C16:1.  C22:6 
was strongly preferred by both ACSL4 and ACSL6_v2 (IC50 = 3 µM and 5 µM, respectively).  
C18:2 and C18:3 were strongly preferred to C16:1 by ACSL4 and ACSL6_v1.  Thus, the 
splice variants of ACSL6 display different substrate preferences despite only 1.7% difference 
in sequence.  These data increased our understanding of enzyme kinetics among ACSL 
isoforms abundant in brain.   
 
6.3 Nutritional regulation of ACSL1 and ACSL4 in rat liver 
    We previously showed that proteins levels of ACSL1, 4 and 5 in rat liver changed 
differently by nutritional status (64,80).  Both ACSL1 (95%) and ACSL4 (64%) increase in 
rats that are refed a high sucrose diet after 48 h fasting, whereas ACSL5 increases 82% after 
fasting 48 h.  To examine whether the response of protein was concordant with the change 
of mRNA, we compared the mRNA and protein levels of ACSL1 and ACSL4 in rat liver, 
under chow fed diet, fasting 48 h, and refeeding with a high sucrose diet 24 h after 48 h 
fasting.  Consistent with previous data, fasting decreased and refeeding increased ACSL1 
protein, and refeeding increased ACSL4 protein in liver (Figure 6.4 A and B).  However, 
the change of mRNA was almost the opposite to that of protein.  Fasting 48 h increased 
ACSL1 mRNA around 25%, which was decreased to only half by refeeding a high sucrose 
diet (Figure 6.4 C).  The mRNA change of ACSL4 showed a similar pattern to ACSL1 
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mRNA.  Our data showed dissociation of the change in mRNA level and the change in 
protein abundance under nutritional change.  It is likely that ACSL isoforms are under 
regulation at post-transcriptional and post-translational levels.  These data also suggest that, 
to understand the function of ACSL and other enzymes in metabolism, determination of 
products from different pathways is necessary in addition to enzyme abundance. 
 
    This is a part of work in a paper published as a co-author (61).  This paper compared 
tissue distribution of all ACSL isoforms in rat, and the response to dietary change in adipose 
tissues, skeletal muscle, and liver.  Isoform-specific distribution and responses supported 
our hypothesis that ACSL isoforms channel acyl-CoAs into specific pathways, and can be 
regulated differently under nutritional conditions.   
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Scheme 6.1.  Construction of shuttle vector containing ACSL1FLAG.  A full-length rat 
ACSL1 cDNA with a C-terminal FLAG epitope (DYKDDDDK) was subcloned from a 
previously constructed pTRE2hyg plasmid into a shuttle vector, pACCMVpLpA at the Bam 
HI and Sal I sites.  Expression of the inserted ACSL1FLAG cDNA is driven by the 
cytomegalovirus promoter (CMV).  The inserted ACSL1FLAG in the 
pACCMV-ACSL1FLAG construct was verified by restriction enzyme analysis and 
confirmed by DNA sequencing at the UNC DNA sequencing facility.   
ACSL1FLAG
ACSL1FLAG inserted
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Scheme 6.2.  General strategy for preparing recombinant adenovirus by homologous 
recombination.  The shuttle vector pACCMV-ACSL1FLAG and virus vector pJM17 are 
co-transfected into 293 cells by calcium phosphate co-precipitation for homologous 
recombination to form recombinant adenovirus carrying ACSL1FLAG cDNA (Ad-ACSL1).  
Adenovirus causes lysis of cells and lysates are collected and transfected to COS7 cells for 
ACS activity check (Figure 6.1B).  Virions from selected lysate are further purified and 
amplified (131).  Purified adenovirus is infected into 3T3-L1 preadipocytes for ACS activity 
check (Figure 6.1C). 
(ACSL1FLAG)
pACCMV-
ACSL1FLAG
ACSL1FLAG
Recombinant Adenovirus 
(Ad-ACSL1FLAG)
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Figure 6.1.  ACS activity check during recombinant adenovirus production.  A) Plasmids 
were transfected into CHO cells and ACS specific activity was measured.  The shuttle 
vector pACCMV-ACSL1FLAG (Scheme 6.2) increases ACS activity, close to original 
pTRE2hyg transfected cells.  B) Lysates from 293 cells after co-transfection were infected 
in COS7 cells, with uninfected and EV infected cells as controls.  Lysate #3 increased ACS 
specific activity the most, and thus was used for virus purification and amplification.  C) 
Purified adenovirus carrying ACSL1FLAG (Ad-ACSL1) was infected in 3T3-L1 
preadipocytes at indicated doses.  ACS enzyme assay was conducted in the presence (filled 
bar) or absence (open bar) of Triacsin C at 10 µM.   
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Figure 6.2.  Expression and purification of recombinant ACSL3-, ACSL4-, ACSL6_v1-, 
and ACSL6_v2-FLAG proteins.   Different fractions in the purification were 
electrophoresed on a 10% acrylamide gel containing 0.1% SDS and stained with Gel Code 
blue stain reagent (Pierce).  The molecular weight markers are on the left (Lane M).  The 
arrow indicates the position of the ACSL-FLAG protein.  Fractions: Lys, lysate; CE, cell 
extract; Me, membrane fraction; Sol, soluble fraction; F, flow through; 1a, 1b, 2, 3 are eluted 
fractions.  ACSL6_v1, ACSL6_v2 and ACSL3 are partially purified, as multiple bands 
indicate.     
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Figure 6.3.   Different substrate preferences among rat ACSL isoforms.  Flag-purified 
ACSL6_v1-Flag ( ), ACSL6_v2-Flag ( ), ACSL3-Flag ( ), and ACSL4-Flag ( ) were 
assayed for ACS activity with 50 µM [14C]palmitate in the absence or presence of unlabeled 
A) linoleic, B) linolenic, C) arachidonic, D) eicosapentaenoic, and E) docosahexaenoic acid 
(0.5 µM to 100 µM). F) Relative IC50 for each fatty acid (51).   
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Figure 6.4.  Expression of ACSL1 and ACSL4 under chow diet, fasting, and refeeding 
after fasting.  Rats (130g, male) were fed a chow diet, fasted for 48 h, or fasted for 48 h and 
then refed a high sucrose diet (60%) for 24 h.  A) Liver were homogenized in buffer 
containing 250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA, and 1 mM dithiothreitol on 
ice.  Homogenates were subject to SDS-PAGE and Western blot with primary antibodies 
against ACSL1 and ACSL4, with antibody against β-actin as loading control.  B) 
Densitometry analysis of ACSL1 and 4 immunoblots normalized to β-actin.  C) RNA was 
extracted (Qiagen RNeasy) and quantified by Applied Biosystems 7700 sequence detection 
system.  Data represent means ± SEM (n = 4).  * p < 0.05 and ** p < 0.01 vs. chow-fed; # 
p < 0.05 and ## p < 0.01 vs. fasted as determined by Student’s t-test (61). 
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